
Contents lists available at ScienceDirect

Developmental Biology



journal homepage: www.elsevier.com/developmentalbiology

Evolution of Developmental Control Mechanisms

Targeted deletion of *Hand2* in cardiac neural crest-derived cells influences cardiac gene expression and outflow tract development

Kristen L. Holler ^a, Tyler J. Hendershot ^a, Sophia E. Troy ^a, Joshua W. Vincentz ^b, Anthony B. Firulli ^b, Marthe J. Howard ^{a,*}

^a Department of Neurosciences and Program in Neurosciences and Degenerative Disease, Health Sciences Campus, University of Toledo, ¹ 3000 Arlington Ave., Toledo, OH 43614-1007, USA ^b Riley Heart Research Center, Herman B Webb Center for Pediatric Research, Indiana Medical School, 1044 W. Walnut St., Indianapolis, IN 46202-5225, USA

ARTICLE INFO

Article history: Received for publication 20 May 2009 Revised 29 January 2010 Accepted 1 February 2010 Available online 6 February 2010

Keywords: Hand2(dHand) Neural crest bHLH Heart Outflow tract Cardiac cushion Cell type-specific gene regulation Gene microarray

ABSTRACT

The basic helix-loop-helix DNA binding protein Hand2 has critical functions in cardiac development both in neural crest-derived and mesoderm-derived structures. Targeted deletion of Hand2 in the neural crest has allowed us to genetically dissect Hand2-dependent defects specifically in outflow tract and cardiac cushion independent of Hand2 functions in mesoderm-derived structures. Targeted deletion of Hand2 in the neural crest results in misalignment of the aortic arch arteries and outflow tract, contributing to development of double outlet right ventricle (DORV) and ventricular septal defects (VSD). These neural crest-derived developmental anomalies are associated with altered expression of Hand2-target genes we have identified by gene profiling. A number of Hand2 direct target genes have been identified using ChIP and ChIP-on-chip analyses. We have identified and validated a number of genes related to cell migration, proliferation/cell cycle and intracellular signaling whose expression is affected by Hand2 deletion in the neural crest and which are associated with development of VSD and DORV. Our data suggest that Hand2 is a multifunctional DNA binding protein affecting expression of target genes associated with a number of functional interactions in neural crest-derived cells required for proper patterning of the outflow tract, generation of the appropriate number of neural crest-derived cells for elongation of the conotruncus and cardiac cushion organization. Our genetic model has made it possible to investigate the molecular genetics of neural crest contributions to outflow tract morphogenesis and cell differentiation.

© 2010 Elsevier Inc. All rights reserved.

Introduction

Proper function of the four-chambered mammalian heart requires that oxygenated blood and deoxygenated blood be routed, respectively, to the systemic and pulmonic circulatory systems. The elegantly structured cardiac outflow tract (OFT) fulfills this task. The OFT is composed of cells derived from both neural crest and splanchnic mesoderm that collectively generate a properly septated ascending aorta and pulmonary artery, which is required for postnatal survival. Cardiac morphogenesis initiates at E7.5 in the mouse where anterior lateral plate mesoderm migrates towards the midline forming a linear heart tube. This early tube gives rise to both right and left atria, the left ventricle, and is defined as the primary heart field. During looping of the primary heart tube, a second distinct population of pharyngeal mesoderm-derived cells, termed the

E-mail address: marthe.howard@utoledo.edu (M.J. Howard).

secondary heart field, contribute to both myocardial and endocardial components of the right ventricle, interventricular septum, venous pole and base of the OFT where it connects to the great vessels. In addition to the mesoderm-derived cells, the OFT acquires a substantial contribution from the cardiac neural crest. A more complete understanding of OFT formation might therefore be based in determining the function of regulatory molecules expressed in both mesoderm-derived and neural crest-derived components. The basic helix–loop–helix (bHLH) DNA binding protein Hand2 is of particular interest as it has critical functions in both mesoderm-derived and neural crest-derived components.

Hand2 is expressed within cells of both the primary and secondary heart fields, as well as cardiac neural crest-derived cells. Cells from the primary heart field contribute to heart formation beginning at the cardiac crescent stage (E7). Transcripts encoding *Hand2* are present in the cardiac crescent but as cardiac looping initiates (E8) *Hand2* expression within the primary heart field down-regulates to be replaced by expression within the forming right ventricle and OFT (McFadden et al., 2000; Firulli, 2003; Barnes and Firulli, 2009). Although systemic knockout of *Hand2* does not directly affect development of primary heart field-derived structures, phenotypic anomalies are observed within the OFT and right ventricle (Srivastava et

 $[\]ast$ Corresponding author. Department of Neurosciences, University of Toledo, 3000 Arlington Ave., Toledo, OH 43614, USA. Fax: +1419 383 3008.

¹ The Medical University of Ohio changed its name to the Health Sciences Campus, University of Toledo following a merger in 2007. Tel.: +1 419 383 5438; fax: +1 419 383 3008.

^{0012-1606/\$ –} see front matter 0 2010 Elsevier Inc. All rights reserved. doi:10.1016/j.ydbio.2010.02.001

al., 1995; Srivastava et al., 1997; Thomas et al., 1998) suggesting a requirement of Hand2 for proper development of these structures. Expression of Hand2 is also crucial for the formation of several neural crest-derived structures including sympathetic chain ganglia (Howard, 2005; Hendershot et al., 2008; Schmidt et al., 2009), cranio-facial elements (Funato et al., 2009) and the enteric nervous system (Wu and Howard, 2002; Hendershot et al., 2007; Morikawa et al., 2007).

A constellation of congenital heart defects (CHDs) including ventricular septal defects, aortic arch artery patterning defects, and aortic and pulmonary valvular defects, is attributed to cardiac neural crest dysfunction; these disorders represent a substantial proportion of all observed CHDs (reviewed in Srivastava and Olson, 2000; Snider et al., 2007; Waldo et al., 1998; Stoller and Epstein, 2005; Lie-Venema et al., 2007; Mitchell et al., 2007; Obler et al., 2008; Snarr et al., 2008). These late-stage phenotypes cannot be assessed in systemic Hand2 knockout mice due to early developmental lethality. To better dissect the molecular mechanisms of Hand2 function specifically in neural crest-derived cells important for OFT morphogenesis and independent from its function in mesoderm-derived components, we took advantage of our floxed-Hand2 mice (Hendershot et al., 2007, 2008). We targeted deletion of Hand2 in the neural crest using the Wnt1-Cre driver line of mice (Danielian et al., 1998; Jiang et al., 2002). Our results demonstrate that targeted deletion of Hand2 in the cardiac neural crest results in embryos with defects in OFT and aortic arch artery development, which phenocopy documented neural crestdependent defects (reviewed in Stoller and Epstein, 2005; Mitchell et al., 2007; Hutson and Kirby, 2007). Our studies confirm and extend previously published aortic arch artery defects in a similar but independently generated Hand2 conditional allele (Morikawa and Cserjesi, 2008), by additional analysis of OFT phenotypic anomalies and analyses of differential patterns of gene expression. We show that targeted deletion of Hand2 results in double outlet right ventricle (DORV) and accompanying ventricular septal defects (VSD). By combining targeted deletion of Hand2 with microarray and ChIP-onchip analyses, we have identified a number of transcriptional regulators and signaling molecules within the neural crest whose expression is modulated by loss of Hand2. Moreover, we show that Hand2 directly regulates a number of genes expressed within the neural crest suggesting a role for Hand2 in mediating transcriptional programs that orchestrate cell-cell interactions within the forming OFT and which affect cell cycle regulation.

Materials and methods

Targeting strategy and mouse strains

All breeding procedures, animal care and experimental protocols were approved by the Medical University of Ohio (renamed University of Toledo Health Sciences Campus) animal care and use committee prior to initiation of this work. Our strategy for targeting *Hand2* is published elsewhere (Hendershot et al., 2007). Our analysis of *Hand2*^{*fl*/*fl*} mice demonstrates that the mice are fertile, viable and phenotypically normal; introduction of *loxP* sites in the 5′ UTR therefore does not negatively impact transcription at the targeted locus. Normal levels and patterns of *Hand2* expression have been confirmed by *in-situ* hybridization and qRT-PCR (Hendershot et al., 2007, 2008). Both systemic and targeted deletion of *Hand2* is

embryonic lethal (Srivastava et al., 1997; Hendershot et al., 2008). To generate embryos older than E11 (Hendershot et al., 2008) pregnant dams are fed water containing a cocktail of catecholamines (100 µg/ml L-phenylephrine, 100 µg/ml isoproterenol, and 2 mg/ml ascorbic acid) beginning at embryonic day (E) 8. This pharmacological approach allows us to rescue $Hand2^{flneo}$ and $Hand2^{fl/fl;Wnt1-Cre}$ embryos from pre-term death, a phenotype observed in other mouse models in which norepinephrine is absent or expression curtailed (Hendershot et al., 2007; Lim et al., 2000; Thomas et al., 1995; Zhou and Palmiter, 1995). Reporter mice were generated as previously described (Hendershot et al., 2007). Homozygous R26RYFP females were mated to hemizygous Wnt1-Cre males and $Hand2^{fl/+;Wnt1-Cre}$ males were mated to $Hand2^{fl/fl;R262YFP}$ females.

Immunocytochemistry and histology

The antibodies used for the current studies are detailed in Table 1. Embryos were prepared and treated as previously described (Hendershot et al., 2007, 2008). Briefly, embryos or tissues are emersion fixed in 4% paraformaldehyde overnight at 4 °C, extensively washed in PBS and stored in 30% sucrose unless otherwise stated. For analysis of heart development, hearts were removed in ice-cold PBS, fixed in 10% neutral buffered formalin, dehydrated through a graded series of ethanol and embedded in paraffin. Paraffin sections were prepared and stained with hematoxylin and eosin (University of Texas, Southwestern Medical center, Molecular Pathology Core Laboratory) using standard procedures. Frozen sections of Hand2^{wt/wt} and Hand2^{fineo/flneo} E11 hearts were stained using a modified hematoxylin and eosin stain (Sanderson, 1994). Briefly, tissue sections were post-fixed in 4% paraformaldehyde (10 min), rinsed in PBS $(2 \times 5 \text{ min})$ and stained in hematoxylin (1 min), followed by washing in running water, differentiation in 1% HCl in 70% EtOH, bluing in Scott's tap water (3.6 g sodium bicarbonate, 20 g magnesium sulphate/litre) with counterstaining in eosin Y for 10-20 s, followed by dehydration and mounting in Permount (Fisher Scientific, Fair Lawn, NJ) or EUKITT (O. Kindler, Germany). Immunostaining was done according to our established procedures (Howard et al., 1999; Wu and Howard, 2002; Liu et al., 2005a,b; Hendershot et al., 2007). Tissue sections were blocked in a solution containing .1 M Tris, pH. 7.5, 1.5% NaCl, .3% Triton X-100 and 10% horse serum for 3×5 min. Primary antibody is applied in this same solution but containing 4% horse serum and incubated overnight at 4 °C. Following washing in .1 M Tris pH 7.5, 15% NaCl, secondary antibody was applied in this same solution with 4% horse serum for three hours at room temperature. Sections are then washed 3×5 min in .1 M Tris, pH 7.5, 15% NaCl and mounted in Vectashield (Vector Laboratories, Burlingame, CA) or Fluoromount-G (Southern Biotech, Birmingham, Al). To view sites of antibody binding in whole embryos (Young et al., 1999; Hendershot et al., 2007, 2008) samples were incubated overnight in PBS containing .3% Triton X-100 with gentle shaking at 4 °C. We used our standard blocking step and primary antibody was applied as described above and incubated for two days at 4 °C with gentle shaking. Following extensive washing secondary antibody was applied and embryos incubated overnight at 4 °C with shaking. Whole embryos were mounted on depression slides in Fluoromount-G (Southern Biotech, Birmingham, AL).

Table 1

Antibodies used for immunostaining in this study are listed. The antigen, dilution, and secondary antibodies are listed. The source for each antibody is listed.

Antigen/antibody	Dilution	Source	Secondary antibody	Dilution	Source
Connexin 40 (rabbit)	1:50	Zymed, Carlsbad, CA	Donkey anti-rabbit TRITC Donkey anti-rabbit Alexa 647	1:200 1:500	Jackson ImmunoResearch, West Grove, PA Invitrogen, Carlsbad, CA
GFP (chicken) Ki-67 (rabbit)	1:300 1:200	Aves Labs, Tigard, OR AbCam, Cambridge, MA	Donkey anti-chicken FITC Donkey anti-rabbit TRITC	1:100 1:200	Jackson ImmunoResearch West Grove, PA Jackson ImmunoResearch West Grove, PA

Confocal microscopy

All confocal images were acquired using a Leica Microsystems multiphoton confocal microscope (TCS SP5). Confocal Z-stack images were captured using either a 10× objective (n.a. = .3) or 63× (oil immersion) objective (n.a. = 1.4) with 4× software magnification at .5 μ m (tissue sections) or 1.0 μ m (whole-mount) steps. To acquire images, fluorescent FITC-coupled, TRITC-coupled and AlexaFlour 647-coupled secondary antibodies were excited using argon, HeNE or 633 laser lines, respectively.

Gene array analysis

For this array (Affymetrix 430 2.0, mouse array) total cellular RNA was isolated from Hand2^{wtwt} and Hand2^{fl/del;Wnt1-Cre} E10.5 hearts using RNeasy (Qiagen, Valencia, CA) according to manufacturer's directions. The RNA samples were submitted to the NIH Neurosciences Microarray Consortium (Phoenix, AZ, USA; http:// arrayconsortium.tgen.org/np2/home.do;) for array preparation and analysis. The screen included three biological replicates for each genotype (3 chips/genotype). Expression and statistical analyses were compiled using GeneSpring (GX V 7.3.1 (Agilent Technologies, Santa Clara CA). The signal intensities from each probe set were normalized at the 50th percentile for each chip; the expression level for each gene was normalized to the median level across the arrays. The linear regression for all replicates was greater than .9 indicating that replicates correlated very well. A list of significantly expressed genes was generated based on a comparison of 3 arrays derived from control and three arrays derived from mutant hearts. The list was filtered first for the absent genes, secondly for a fold change cutoff of 2, and thirdly for *P* value of $\leq .05$ using Welch's *t*-test. Genes whose expression was significantly altered by Hand2 deletion in the neural crest were subjected to network analysis using GeneGo (St. Joseph, MI), MetaCore and amiGO to group genes based on function and/or pathway analysis. We chose genes for further analysis based on their fold change, relationship to Hand2 and cardiac development.

Real-time RT-PCR

Expression of transcripts encoding proteins identified in the gene array analysis were verified using quantitative reverse transcription-real time PCR as previously described (Zhou et al., 2004; Liu et al., 2005b; Hendershot et al., 2008). Briefly, we calculated the levels of transcript from the Ct values and normalized them based on expression of GAPDH. A detailed description of the protocol and equations can be found in Zhou et al. (2004) or Liu et al. (2005b). Each triplicate sample was analyzed (in triplicate) using cDNA corresponding to 10 ng of input RNA isolated from either Hand2^{wt/fl} or Hand2^{fl/del;Wnt1-Cre} E10.5 hearts. cDNA was mixed with Tagman Gene Expression master mix (Applied Biosystems, Foster City, CA, USA) and premixed $(20\times)$ Taqman probes $(5 \mu M)$ and primers $(18 \mu m)$. Forward and reverse primers (1.1 µM final concentration) with 6-FAM (carboxyfluorescein reporter dye) and a non-fluorescent quencher dye incorporated at 5' and 3' ends, respectively were used for all assays. Primers and probes were purchased from Applied Biosystems (Foster City, CA, USA) from their inventory of pre-developed Taqman® Gene Expression Assays. Triplicate PCR reactions were run and analyzed using a 7500 Fast Real-Time PCR sequence detection system (Applied Biosystems); the increase in product is monitored directly and reflects the threshold number of cycles (C) required for a detectable change in fluorescence based on release of probe. The efficiency of each primer and probe set was determined in separate reactions and based on the slope of C vs. input cDNA dilution. Efficiency values were \geq 1.875 for all transcripts.

To determine whether Cx40 is a direct Hand2 target, we employed Chromatin Immunoprecipitation (ChIP) on genomic DNA cross linked, immunoprecipitated and purified from H92c cells, using a protocol modified from manufacturer's guidelines (Millipore Corp., Billerica, MA). Briefly, $\sim 1 \times 10^6$ H9c2 cells ($\sim 75\%$ confluent, 10 cm dish) were cross linked in 1% formaldehyde for 10 min at RT. Cross linking was quenched in 1 ml of 1.25 M glycine in PBS with shaking for 5 min at RT. Cells were rinsed twice with ice-cold PBS, collected to 1.5 ml Eppendorf tubes, and pelleted at $2000 \times g$ for 4 min at 4 °C. Cell pellets were washed with 1 ml of PBS containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml pepstatin, Roche Inc., Madison WI) then resuspended in 200 µl of lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-Cl, pH 8.1, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml pepstatin). The cell suspensions were incubated on ice for 10 min and sonicated on ice 4 times, 30 s each, at 1 minute intervals using a setting of 3 (Fisher Scientific Model: 550 Sonic Dismembrator). The appropriate sonication protocol was determined empirically. Lysates were centrifuged (1000 rpm, 7 min) and supernatants were added to 1.8 ml of dilution buffer (1.1% Triton X-100, .01% SDS, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris-HCl, pH 8.1, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, $1 \mu g/ml$ pepstatin), then pre-cleared with 50 μ l of Protein A/G PLUSAgarose (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 1 h with end-over-end rotation at 4 °C. Protein A/G PLUSAgarose was removed by brief centrifugation and immunoprecipitation was performed overnight at 4 °C with 5 µg of Hand2 antibody.

The following day, an additional 50 µ1 of Protein A/G PLUSAgarose was added and the incubation continued for 2 h at 4 °C. Immunocomplexes were collected by centrifugation at 1000 rpm for 1 min at 4 °C and subjected to sequential 5 minute washes in 1 ml of each of the following buffers: low salt immune complex wash buffer (1% Triton X-100, .1% SDS, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), high salt immune complex wash buffer (1% Triton X-100, .1% SDS, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl), and LiCl immune complex wash buffer (.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1). Precipitates were washed twice with TE buffer, then eluted twice in 250 µl of elution buffer (1% SDS, .1 M NaHCO₃) for 15 min at RT. The eluates were pooled and 20 µl of 5 M NaCl was added; the eluates were subsequently heated at 65 °C for 4 h. Protein was removed from the samples by addition of 10 µl .5 M EDTA, 20 µl 1 M Tris-HCl, pH 6.5 and 1 µl of 20 mg/ml Proteinase K for 1 h at 45 °C. DNA fragments were recovered by phenol/chloroform extraction and ethanol precipitation; 10 µg of yeast tRNA was added to each eluate to aid in recovery of DNA pellets. Following centrifugation $(12,000 \times g,$ 20 min at 4 °C), the pellets were resuspended in 50 µl of TE; 1 µl was used per PCR reaction. PCR primers were as follows: Cx40(F) ChIP[-1144]: 5'-ACTGTCCCTCAGTTTCCCTG-3', Cx40(R)ChIP [-814]: 5'-ACAGAGGGTCAAGGACATGG-3', Cx40(F)ChIP[-655]: 5'-GAACACTCTGATTGGTGGGG-3', Cx40(R)ChIP[-283]: 5'-CCAGTGGCTGTCCTTGTTTT-3', GAPDH: 5'-TCCCACTCTTCCACCTTC-3', GAPDH: 5'-CTGTAGCCGTATTCATTGTC-3'. PCR was conducted using GoTaq polymerase (Promega Corp., Madison, WI) with a 58 °C, 1 min annealing step over 40 cycles of amplification.

ChIP-on-chip

Neural crest-derived cells were FACsorted from 20 E10.5 hearts isolated from wild-type Wnt1-reporter embryos and samples were prepared according to the manufacturer's ChIP-chip user's guide (Roche NimbleGen, Inc. Madison, WI). Briefly, hearts were extensively washed in ice-cold PBS, incubated in .5% trypsin in CMF-PBS for 15 min and dissociated into single cells using a fire-polished Pasteur pipette. The

cells were washed one time in PBS, pelleted, and cross linked in 1% formaldehyde for 8 min at RT. The cross linking was quenched in 125 mM glycine. The washed cells were filtered through a 70 µm nylon cell strainer (Falcon #352350, Bedford, MA) and subjected to FACsorting (BDFacs Aria, BD Biosciences, San Jose, CA); the non-neural crest cells from the non-sorted sample were used for the controls. The sorted neural crest cells were lysed and sonicated (Fisher Scientific Model: 550 Sonic Dismembrator) for 4 rounds for 15 s on a setting of 3 with a one minute incubation on ice in between each round. The appropriate settings for sonication were determined on genomic DNA and the fragment size verified in a 1% agarose gel. For IP, we used our Hand2 antibody (raised in rabbit) coupled to Dynabeads (M-20, Invitrogen, Carlsbad, CA). Complexes were allowed to form for 2 h at 4 °C with rotation and isolated on a magnetic table. Sample DNA was amplified according to manufacturer's directions (WGA3, Sigma-Aldrich, St. Louis, MO) and sent to Roach for processing (2.1×10^6) Deluxe Promoter Array).

Transfection and luciferase reporter assay

HEK293a cells were grown in DMEM plus 10% FBS supplemented with L-glutamine, Na-pyruvate and 100 mg/ml Pen/Stryp (Invitrogen, Carlsbad, CA); cells were transfected when 50% confluent using CaPO₄ according to our published procedures (Firulli et al., 1994). In each well, 2.5 μ g of pcDNA-Hand2 and/or pCS2-MT + E12 (plus empty pcDNA vector to make a total of 5 μ g of plasmid DNA) was co-transfected with 5 μ g of *Cx40* luciferase reporter (Cx40 + pXP2) and 150 ng of *Renilla* reporter (pRL-CMV) as a transfection control. Cultures were harvested 48 h after transfection and diluted ~10 fold in lysis buffer; 50 μ l of this lysate was assayed. Luciferase assays were performed as previously reported (Xu et al., 2003) using the dual luciferase assay kit (Promega Corp., Madison, WI) according to the manufacturer's protocol. Luciferase activities were read using a 96-well microtiter plate luminometer (Thermo Labsystems, Franklin, MA). Assays were done in triplicate.

Statistics

Data are presented as the mean \pm S.E.M. unless otherwise stated. Statistical significance was determined using Student's unpaired *t*-test or ANOVA and Bonferroni post hoc test, unless otherwise stated. At least four embryos were examined for each condition from at least three different matings unless otherwise stated. For microarray analysis, three biological replicates were run and each in triplicate.

Results

Hand2 misexpression affects heart development

In order to define the molecular basis for defects in heart development associated with loss of Hand2 function, we generated a conditional targeted mutation of Hand2 (Hendershot et al., 2007, 2008). For the current studies, we targeted deletion of Hand2 specifically within neural crest-derived cells by intercrossing our compound heterozygous floxed-Hand2 (Hand2^{f/Idel}) mice with mice expressing Cre recombinase under control of the Wnt1 promoter. The Wnt1-Cre transgene allows floxed genes to be targeted in the neural crest (Danielian et al., 1998; Jiang et al., 2000; Brewer et al., 2004; Hendershot et al., 2008). Because loss of Hand2 expression within neural crest-derived cells is embryonic lethal between E10 and E11 due to insufficient levels of norepinephrine (Lim et al., 2000; Hendershot et al., 2008), we routinely feed pregnant dams a cocktail of catecholamine intermediates beginning at E8 (Lim et al 2000; Thomas et al., 1995; Zhou and Palmiter, 1995; Kaufman et al., 2003; Hendershot et al., 2008). This pharmacological rescue makes it possible to bring embryos to term, allowing assessment of Hand2 loss-of-function within neural crest-derived cells and tissues, throughout late-stage OFT morphogenesis and up to birth. *Wnt1*-mediated deletion of *Hand2* results in developmental defects in all neural crestderived structures dependent upon *Hand2* for early aspects of their development (Hendershot et al., 2007, 2008). Briefly, there is significant loss of sympathetic and enteric neurons, alterations in neurotransmitter expression and regulation, as well as a number of defects in cranio-facial development, consequent to the loss of *Hand2*.

We previously reported that embryos harboring the neomycin cassette (Hand2^{flneo/flneo}) in their genome misexpress Hand2 resulting in a Hand2 hypomorph (Hendershot et al., 2008). Interestingly, the impact of Hand2 under-expression was observed to be tissue dependent demonstrating both gene dosage and penetrance effects. The importance of *Hand* gene dosage for cardiac development is well documented (McFadden et al., 2005) and this current study confirms and extends these previous findings. At E18 we observe differential effects on heart development in Hand2^{flneo/flneo} embryos compared to Hand2^{fl/fl} embryos (Fig. 1). In Hand2 hypomorphic (Hand2^{flneo/flneo}) embryos, under-expression of Hand2 could be affecting neural crestderived structures, primary heart field myocardium, and/or intraventricular septal myocardium derived from the second heart field. In the cardiovascular system, the neural crest makes contributions to the aortic arch arteries and OFT. In *Hand2*^{flneo/flneo} embryos, there were no obvious developmental defects within the aortic arch arteries (one embryo had patent ductus arteriosus); ~50% of hearts examined showed membranous VSDs (not shown). Development of the right ventricle is dependent upon Hand2 but independent of the neural crest (Srivastava et al., 1997; Thomas et al., 1998; Srivastava, 1999). Development of the right ventricle was affected in all hypomorphic hearts examined (Fig. 1B). In these hearts ventricular hypoplasia and disorganized trabeculations indicate likely effects on proliferation and/ or apoptosis of cardiomyocytes. We have previously reported that Hand2 regulates proliferation of neural crest-derived noradrenergic neural precursor cells and neuroblasts (Hendershot et al., 2008) suggesting a potential function for Hand2 in the heart (see data below). The hypomorph phenotype thus recapitulates some of the defects observed in *Hand2* systemic null embryos (Thomas et al., 1998; McFadden et al., 2005). Since we were interested in dissecting the function of Hand2 in cardiac neural crest-derived structures and given this potential complication, we employed SYCP-Cre mice to remove the neomycin-resistance cassette within our Hand2 conditional allele and completely rescue these hypomorphic defects (Hendershot et al., 2008).




Fig. 1. Cardiac development is affected in *Hand2* hypomorph embryos. Whole hearts were removed from $Hand2^{fl/f}$ [A] and $Hand2^{flneo/flneo}$ [B] E18.5 embryos and 20 µm frozen transverse sections were visualized following staining with hematoxylin and eosin. Misexpression of *Hand2* [B] consistently results in enlarged hypoplastic right ventricles and disorganized trabeculations. Abbreviations: right ventricle (RV), left ventricle (LV), and aorta (Ao). Scale bars indicate 100 µm [A, B] and 25 m [A1, A2, B1, B2].




Fig. 2. Conditional deletion of *Hand2* effects outflow tract development. Whole hearts were removed from $Hand2^{fl/fl}$ (WT) [A] and $Hand2^{fl/fl;Wnt1-Cre}$ (-/-) [B, C] embryos, embedded in paraffin and 20 µm transverse sections stained with hematoxylin and eosin. In all mutant embryos examined (5) we observed membranous VSDs (B, black arrow) and double outlet right ventricle (C, DORV, arrows). Based on the expression pattern of GFP in comparable cryosections of E18.5 $Hand2^{wt/wt;Wnt1-Cre/R26RYFP}$ reporter [D] and $Hand2^{fl/fl;Wnt1-Cre/R26RYFP}$ mutant reporter [E–F] embryo hearts, the defects that we observe following deletion of Hand2 can be ascribed to neural crest-derived anomalies. Abbreviations: conotruncus (CT) and aorta (Ao).

Targeted deletion of Hand2 results in outflow tract defects

Based on the expression pattern of Hand2 within the cardiac neural crest, we predicted that deletion of Hand2 specifically within this cell population would adversely affect proper development of outflow tract structures. Analysis of Hand2 loss-of-function within the neural crest consistently demonstrated effects on ventricular septation and alignment of the great vessels (Fig. 2). We consistently observed double outlet right ventricle (DORV) with an associated membranous VSD in all *Hand2*^{fl/fl;Wnt1-Cre} embryos (Figs. 2B, C) examined. This neural crest-derived anomaly (DORV) was never observed in Hand2 hypomorphic embryos. Analysis of *Hand2^{wt/wt;Wnt1-Cre;R26R/YFP* mice (Fig. 2D)} and *Hand2*^{fl/fl;Wnt1-Cre/R26R/YFP} mutant reporter mice (Figs. 2E, F) demonstrates that Hand2 will be recombined in the neural crest-derived cells which contribute to the conotruncus and aortic arch arteries. The effect of misexpression of Hand2 within the heart therefore depends heavily upon Hand2 expression levels as well as the identity of the cells where expression of Hand2 is affected.

Defects in neural crest migration and proliferation

Between days E10 and E13 in the mouse, the neural crest not only remodels the pharyngeal arches, contributing to the smooth muscle of the forming arch arteries, but also invades the OFT to form the septum that divides the aorta and pulmonary trunk (Conway et al., 1997, 2000; Snarr et al., 2008). We considered that aberrant migration of neural crest-derived cells into the OFT might contribute to the VSDs observed in all embryos deficient in expression of *Hand2* in neural crest-derived cells. At E10.5 neural crestderived cells have migrated into the OFT traversing approximately 50% of this developing structure (Fig. 3). The patterns of migration observed in *Hand2^{wt/wt;R26R/Wnt1-Cre* and *Hand2^{fl/del;R26R/Wnt1-Cre* E10.5 reporter embryos is strikingly affected by deletion of *Hand2*. At this stage of development it is possible to observe the "prongs" of neural crest-derived cells that will migrate into the truncal cushions (arrows in Figs. 3A, C) and which contribute to septation of the aorta and pulmonary arteries. Visual inspection suggests that loss}} of *Hand2* negatively impacts cell migration and/or cell numbers. There is a dramatic reduction in the number of neural crest-derived cells within the OFT (compare Figs. 3B, D). The migration of neural crest-derived cells into the aortic sac and truncus is not only required for septation but elongation of the conotruncus as well (Waldo et al., 1999; Epstein et al., 2000; Snider et al., 2007). Examination of neural crest-derived cells (Figs. 3B, D) actively migrating into this region suggested that cell-cell interactions are important. It appears that neural crest-derived cells being in contact with their neighbors. In the *Hand2^{fl/del;Wnt1-Cre:R262RYFP* hearts we observe not only fewer cells that have reached the truncus but in addition they appear to migrate more as individual cells with fewer contacts with neighboring cells.}

Based on our previous findings indicating that *Hand2* is required to generate the appropriate number of neuronal precursor cells and neuroblasts in developing noradrenergic sympathetic ganglia (Hendershot et al., 2008) we counted the number of cells expressing the proliferation marker Ki-67 at E10.5 in *Hand2^{wt/wt;Wnt1-Cre:R26RYFP* and *Hand2^{fl/del;Wnt1-CreR262RYFP* hearts. The number of GFP (YFP) marked neural crest cells that labeled for immunoreactivity to Ki-67 was determined on 20 µm frozen cross sections at the level of the OFT (Fig. 4). Cells were counted in the entire outflow tract of control and mutant hearts. In control embryos, the mean number of proliferating neural crest-derived cells per tissue section in the OFT was 47 ± 6 compared to 10 ± 2 (*P*<.01) in the mutant OFT. Based on the number of neural crest-derived cells (GFP) migrating into and within the OFT, we observed a significant reduction in the proportion of proliferating cells based on the total neural crest cell population (Fig. 4G); in}}




Fig. 3. Conditional deletion of *Hand2* effects cell-cell interactions and migration of cardiac neural crest-derived cells. Migrating neural crest-derived cells were visualized in E10.5 *Hand2^{wt/wt;Wnt1-cre/R26RYPP* reporter [A–B] and *Hand2^{ll/del;Wnt1-cre/R26RYPP* mutant reporter hearts [C–D] immunostained for YFP expression in whole-mount. Confocal optical sections (1 µm) were compressed into a z-stack (~400 sections) and analyzed. The pattern of migrating neural crest-derived cells observed within the outflow tract of mutant embryos was strikingly affected by loss of *Hand2* expression. Neural crest-derived cells failed to migrate as a sheet and individual cells appear to have lost apparent contact with their neighbors routinely observed in control migrating cells (compare panels B and D). The number of neural crest-derived cells localized within the conotruncus (white arrows) appears reduced (see Fig. 4) and the patterning of the AP Prongs is defective in the mutant compared to control hearts. The insets show high power views of the area indicated by the (*).}}




Fig. 4. *Hand2* affects proliferation of cardiac neural crest-derived cells. To determine if the apparent decrease in neural crest-derived cells migrating within the outflow tract of $Hand2^{Pl/del;Wht1-Cre;R26R/YFP}$ hearts was due to a defect in cell proliferation, we determined the number of neural crest-derived cells expressing the proliferation marker, Ki-67 in E10.5 outflow tract of $Hand2^{Wht1-Cre;R26R/YFP}$ reporter [A, C, E] and $Hand2^{Pl/del;Wht1-cre;R26RYFP}$ mutant reporter hearts [B, D, F]. Cells were visualized, following immunostaining for Ki-67 (red) and GFP (green; marks YFP expressing neural crest-derived cells) in 20 µm frozen cross sections. There was no apparent difference in the number of cells expressing Ki-67 localized to second heart field. Visual inspection of the entire set of sections encompassing the developing outflow tract indicated a substantial decrease in the number of neural crest-derived cells (green) and neural crest-derived cells proliferating (green + red) within the outflow tract of mutant [B, D] compared to control [A, C] hearts. This result was quantified [G] by counting the number of cells co-expressing GFP and Ki-67 over the entire length of the outflow tract (N = 3 for each genotype). There was a significant (P<.001) decrease in the number of proliferating neural crest-derived cells in response to targeted deletion of Hand2. [H] The percentage of mitotic figures did not differ significantly in control compared to mutant OFT.

control embryos $41\% \pm 4$ of neural crest-derived cells were proliferating compared to $24\% \pm 3$ (*P*<.05) in the mutant outflow tract. This result suggested possible impact of loss of *Hand2* on mitosis. To determine if the number of cells in mitosis was affected by loss of Hand2, we counted the number of mitotic figures in the OFT of *Hand2^{wt/wt;Wnt1-Cre;R26RYFP* and *Hand2^{fl/del;Wnt1-CreR262RYFP}* E10.5 embryos labeled with Ki-67 (Figs. 4E, F, H). The percentage of mitotic figures in *Hand2^{fl/del;Wnt1-CreR262RYFP* OFT was not significantly different from control indicating that equivalent numbers of neural crestderived cells initiated mitosis; this likely results from problems in}} either G1 or S phases of the cell cycle. This suggests that the effects we observe on proliferation likely reflect alterations in the regulatory mechanisms controlling transit through the various stages of mitosis.

Outflow tract defects associated with altered gene expression

In order to directly address the genetic basis of the OFT phenotype we observe in *Hand2*^{fl/del;Wnt1-Cre} embryos, we compared the panel of transcripts whose expression was altered in mutant compared to wild-type embryos. We screened gene arrays using RNA isolated from




Fig. 5. Functional classes of differentially regulated genes in the hearts of *Hand2^{wt/wt}* and *Hand2^{fl/del;wnt1-cre*} embryos. Regulated genes were grouped into 11 functional categories and graphed as a percentage of the total based on their GeneGo designation. 309 genes were differentially regulated based on analysis of the array data; 79 of these regulated genes did not have any known function and were eliminated from this analysis [A]. Of the regulated genes, 68 were up-regulated [B] and 162 were down-regulated [C]. A number of down-regulated genes (17) are associated with cell adhesion; none of the genes in this category was up-regulated. The cytoskeletal-related transcript category contained 16 down-regulated genes and 2 up-regulated genes. In the transcription factor category, a notable difference in the number of transcripts down-regulated (17) and up-regulated (4) related to *Hand2* was observed. In the kinases/phosphatases category a significant number of transcripts (11 up-regulated, 11 down-regulated) were affected by *Hand2* deletion. We have identified a number of Hand2-target genes in each of these categories that are associated with the developmental anomalies that we observe in embryos with targeted deletion of *Hand2* in the neural crest.

E10.5 Hand2^{wt/wt} and Hand2^{fl/del;Wnt1-Cre} whole hearts. The screen included three biological replicates for each genotype (9 chips/ genotype). Our results demonstrate that targeted deletion of Hand2 in neural crest-derived cells in the heart significantly (P<.05) affected expression of 309 identified transcripts and 56 unidentified transcripts regulated minimally by greater than or equal to a 2-fold change (Fig. S1). The identified transcripts were associated with 11 functional classes (Fig. 5A; GeneGo Inc., St. Joseph, MI). Of the identified regulated genes, 68 were up-regulated (Fig. 5B) and 162 were down-regulated (Fig. 5C). Of the identified genes (309) 79 proteins were identified but which have no known function. Of the genes regulated, a notable fraction is known to affect heart development and/or cardiac function (Table 2). We validated a set of genes whose apparent function is associated with some aspect of the morphological or functional consequences of Hand2 deletion; a subset of these genes were validated using RNA purified from cardiac neural crest-derived cells FACsorted from E10.5 heart showing that our transcript analysis yielded alterations in expression of neural crest-specific genes (* in Table 2).

Genes associated with neural crest cell migration

In our initial analysis of the consequences on heart development due to targeted deletion of *Hand2* in the neural crest, we observed that population of the conotruncus by neural crest-derived cells was aberrant (Fig. 3). Several genes associated with migration were differentially expressed in the *Hand2*^{fl/del;Wnt-Cre} mice. These regulated genes fall into at least three functional networks (Table 2). We validated genes from each group using qRT-PCR and/or immunostaining. We observed a decrease in transcript encoding Pdgf (\downarrow 3.89); Pdgf has been associated with neural crest cell migration (Orr-Urtreger and Lonai, 1992). Interestingly, defects in the Pdgf receptor results in developmental defects in the OFT as well as other neural crest-derived structures (Morrison-Graham et al., 1992). We validated *integrin* α 9 (*Itga*9; \uparrow 2.94) because it has an important function in angiogenesis (Brooks et al., 1994), which is adversely affected in *Hand2* mutant embryos (and see Morikawa and Cserjesi, 2008) as well as a potential role in cell migration (Young et al., 2001; Huang et al., 2005). The *integrin subunit* $\alpha 4$ is a component of the $\alpha 4b1$ fibronectin-binding domain, which is one important interaction regulating cell migration (Sheppard et al., 1994; Pinco et al., 2001), and was up-regulated ($\uparrow 3.83$) in response to deletion of *Hand2*. Interestingly, *Adam19* ($\downarrow 2.16$) inhibits migration mediated by $\alpha 4b1$ integrins (Huang et al., 2005). Deletion of $\alpha 4$ *integrin* is embryonic lethal in part due to defective development of the epicardium and coronary vessels (Yang et al., 1995).

The regulation of connexin 40 (Cx40; Gja5) was of particular interest because it is heart-specific (Dahl et al., 1995; Kirchhoff et al., 2000) and associated with both adhesion and cell-cell communication. Based on the array results, transcripts encoding Cx40 were down-regulated 24-fold in Hand2^{fl/del;Wnt1-Cre} hearts compared to control; this transcript was not detectable by qRT-PCR in the linear range of amplification (transcript became detectable at 40 cycles of amplification). We used immunostaining and confocal microscopy to visualize sites of Cx40 expression on tissue sections of E10.5 OFT (Fig. 6). Interestingly, although we could not detect transcripts encoding Cx40 there remains a small number of cells (Figs. 6B, D, F, arrows) that express Cx40 protein in the mutant OFT. The majority of neural crest-derived cells express Cx40 in the wild-type OFT, a novel finding in itself (Figs. 6A, C, E). Connexin 40 is also expressed in some cells in the second heart field-derived component of the conotruncus in both the control and mutant hearts (white arrows Figs. 6A, B) validating that neural crest-specific deletion of Hand2 is revealing a cell autonomous effect. We further assessed regulation of Cx40 because it has not previously been reported in the neural crest and is affected cell autonomously by Hand2 loss-of-function.

Hand2 binds to and trans-activates the Cx40 promoter

We sought to validate that a subset of the genes identified in our microarray screen represent direct Hand2 transcriptional targets

Table 2

Migration Cap1 7.7.8 Itga4 Cytoskeleton Migration Cap2 7.2.59 Mmp14 .06031 Cytoskeleton Nr4a2 2.11 0 Transcription factor Pard3 4.2.11 0 Carascription factor Nav1 2.43 .00376 Cytoskeleton Nav1 2.43 .0488 Cytoskeleton Focal adhesion Itga9* 7.2.94 .0671 Cell adhesion Coll adhesion Itga9* 7.2.94 .0671 Cell adhesion Ligand Gja5* 123.87 .0134 Transcription factor Chanel/transporter Cell cycle/proliferation Cytoskeleton Conbin 1*32.47 .009 Transcription factor Cytoskeleton Conbin 1*32.47 .00464 Transcription factor Transcription factor Stat5b 72.05 .00464 Transcription factor .0121 Facytophystase Tall 2.225 .0124 Transcription factor .0216 Transcription factor Rps6 1.202 <	Biological function	Gene network	Gene symbol	Expression	ChIP-on- chip (FDR)	Classification
Migration Cap1 7.78 Cytoskeleton Itga4 73.83 0.6031 Cytoskeleton Mmp14 2.02 .0201 Enzyme Nr4a2 J.11 0 Transcription factor Pard3 J.211 .003 Cell adhesion Ankrd6 J.219 .00076 Cytoskeleton Nav1 J.2.43 .0488 Cytoskeleton Focal adhesion Itga9* 12.94 Receptor Col11a1* J.21 .051 Cell adhesion Focal adhesion Itga9* 12.94 Receptor Col11a1* J.207 .009 Transcription factor Ligand Transcription factor Ligand Ligand Sox11* J.207 .009 Transcription factor Cytoskeleton Carbin 12.11 .071 Enzymes Cdk6 12.53 Kinase/phosphatase Rinase/phosphatase Rinase/phosphatase Prig1* 7.11 J.2225 .04440 Transcription factor	Migration				-	
Clasp2 12.59 .06031 Cytoskeleton Mmp14 J.202 .0201 Enzyme Nr422 J.211 0 Transcription factor Pard3 J.211 .003 Cell adhesion Ankrd6 J.219 .0076 Cytoskeleton Nav1 J.243 .0488 Cytoskeleton Focal adhesion Itga19* 7.2.94 Receptor Focal adhesion Itga19* 7.2.94 Receptor Cell cytel/proliferation Cga5* J.237 .0671 Cell adhesion Cytoskeleton Choling 32.47 .0134 Transcription factor Cytoskeleton Cell 2.53 .0134 Transcription factor Cytoskeleton Choling 32.47 .19718 Enzymes Kinase/phosphatase Eif2ak1 2.61 .10235 Kinase/phosphatase Ptg1* 72.11 Sta55 .203 .17212 Adaptor/regulator Hoxa3 J.2.15 .15815 Transcription factor Sta11* <		Migration	Cap1	17.78		Cytoskeleton
Mmp14 J202 J201 Enzyme Nr4a2 J2.11 0 Transcription factor Pard3 J2.11 J003 Cell adhesion Ankrd6 J2.19 J0076 Cytoskeleton Nav1 J2.43 J488 Cytoskeleton Focal adhesion Itga9* T2.94 Receptor Focal adhesion Itga9* T2.94 J171 Coll1a1* J2.1 J0671 Cell adhesion Tanscription factor Gj45* J2387 Chamel/transporter Cell cycle/proliferation Conhip T32.47 J1718 Enzymes Cytoskeleton Conhip T32.47 J216 J10235 Kinase/phosphatase Fitzaki T2.16 J10235 Kinase/phosphatase J114 J202 J218 Tanscription factor Stat55 T2.05 J0464 Transcription factor Tanscription factor Tanscription factor Gamb2 J215 J17212 Adaptor/regulator Hoxa J22.5 Nucleotide binding<			ltga4	13.83		Receptor
Nr42 \downarrow			Clasp2	12.59	.06031	Cytoskeleton
Pard3 $J_2.11$.003Cell adhesionAnkrd6 $J_2.19$.0076CytoskeletonNav1 J_2A3 .0488CytoskeletonFocal adhesionItga9* $T_2.94$.0671Cell adhesionPdgD* $J_3.89$.0256Transcription factorReceptor.011 a1* $J_2.07$.009Transcription factorColl ages $J_2.387$.0134Transcription factorCell cycle/proliferation.0235Kinase/phosphataseCytoskeletonCcnb1ip $T_2.16$.00235CytoskeletonCcnb1ip $T_2.16$.00235Nmm14 $J_2.02$.021EnzymesCdk6 $T_2.53$.00464Transcription factorMmp14 $J_2.02$.021EnzymeRps6 $J_2.03$.17212Adaptor/regulatorHoxa3 $J_2.15$.15815Transcription factorCamk2a $J_2.17$.07472Kinase/phosphataseTial1 $J_2.22$.0069Nucleotide bindingFoxC1* $J_3.73$.0256Transcription factorSox11* $J_2.55$.0134Transcription factorSox11* $J_2.55$.0134Transcription factorCamk2a $J_2.17$.0565Transcription factorNucleotide bindingTranscription factorNucleotide bindingFoxC1* $J_3.73$.0256Transcription factorRps6 $J_2.55$.0134Transcription factorRps7 $J_3.74$.03556Transc			Mmp14	↓2.02	.0201	Enzyme
Ankrd6 \downarrow 2.19 Nav1.00076Cytoskeleton CytoskeletonFocal adhesionItga97.2.94 ReceptorReceptor Coll1a1*.0671Cell adhesion Itga9Focal adhesionItga97.2.94 Receptor.0671Cell adhesion ItgandPdgD7J.2.5.0134 Transcription factor Cja5*.0314 J.2.5Transcription factor Channel/transporterCell cycle/proliferationCorb1ip 1 2.2.47 Ctdk6.0971 Transcription factor Kinase/phosphatase Eif2ak1.19718 			Nr4a2		0	Transcription factor
Nav1J.2.43 FOCAl adhesionOdd88 FOCC1*Cytoskeleton ReceptorFocal adhesionHigg9* Tigg9*J.2.94 LiggandOG71 Cell adhesionPdgfD*J.3.89 J.2.57J.0134 Transcription factorPdgfD*J.2.57 L.2.57J.0134 Transcription factorCell cycle/proliferationCytoskeletonCcnb1ip Cig15*CytoskeletonCcnb1ip Cig15*1.9718 L.2.57 L.2.53Enzymes Kinase/phosphataseFrig1*T.2.16 Transcription factor1.00235 Transcription factorStat5b7.205 L.2.03J.00464 Transcription factorMmp14J.2.02 L.2.02J.17212 L.2.44 Adaptor/regulatorHoxa3 Fox2*J.2.15 L.15815Transcription factor Transcription factorMmp14J.2.22 L.2.02J.0024 L.2.17Enzyme Rys6 L.2.03Fox1*J.2.15 L.15815Transcription factor Transcription factorGamk2aJ.2.17 L.17J.7472 Transcription factor Transcription factor Transcription factorGi3J.3.54 L.2.55J.0134 Transcription factorFoxC1*J.3.73 L.2.55J.0256 Transcription factorFoxC1*J.3.73 L.2.55J.0235 Transcription factorFoxC1*J.3.73 L.2.55J.0235 Adaptor/regulatorHard morphogenesisIfga4 T.3.73 L.2.73J.0236 L.2.74Heart morphogenesisIfga4 L.2.17 L.3.73J.0235 L.2.172Heart morphogenesisIfga4 L.3.73 L.3.73J.0671 L.2.12 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Focal adhesionFoxC1* $4.3.78$ T2.94 Coll1a1* 0.256 ReceptorTranscription factor 						5
Focal adhesionItga9* 12.94 Col11a1* 0.671 Cell adhesionPdgf0* 43.89 Sox11* $J2.5$ 0.134 Transcription factorInsm1* $J20.7$ 0.09 Transcription factorCell cycle/proliferationCcnb1ip 132.47 19718 EnzymesCdk6 12.53 10235Kinase/phosphataseEif2ak1 12.16 10235 Kinase/phosphatasePttg1* 12.11 Transcription factorStat5b 12.02 00464 Transcription factorMmp14 $J2.02$ 00464 Transcription factorMmp14 $J2.02$ 00464 Transcription factorMmp14 $J2.02$ 0014 Transcription factorCamk2a $J2.15$ 15815 Transcription factorCamk2a $J2.15$ 00609 Nucleotide bindingFoxp2* $J2.45$ Transcription factorSox11* $J2.5$ 0134 Transcription factorLgals7 $J3.01$ 01206 Cell adhesionGli3 $J3.54$ 03856 Transcription factorRpL17 $J5$ 10235 Adaptor/regulatorHeart morphogenesisItga4 13.83 0671 Heart morphogenesisItga4 13.54 03856 DifferentiationYwhag 2.1 003 RpL17 $J5$ 10235 Adaptor/regulatorHeart morphogenesisItga4 13.83 06671 Cell adhesionCija5* $J2.387$ Channels/transporter<						
$\begin{array}{cccc} Coll 1a1^* & \downarrow 2.1 \\ Pdgfb^* & \downarrow 3.89 \\ Sox11^* & \downarrow 2.5 \\ Insmit^* & \downarrow 2.07 \\ Gja5^* & \downarrow 2.387 \end{array} \begin{array}{c} 0.134 \\ Transcription factor \\ Camel/transporter \end{array} \\ \hline Cell cycle/proliferation \\ Cytoskeleton \\ Cytoskeleton \\ Cytoskeleton \\ Cytoskeleton \\ Cytoskeleton \\ Cytoskeleton \\ Camel/table \\ Pitg1^* & 12.16 \\ Stat5b \\ Pitg1^* & 12.11 \\ Stat5b \\ Pitg1^* & 12.11 \\ Stat5b \\ Pitg1^* & 12.11 \\ Stat5b \\ Transcription factor \\ Hoxa3 \\ \downarrow 2.15 \\ Transcription factor \\ Camk2a \\ \downarrow 2.17 \\ Ode44 \\ Transcription factor \\ Transcription factor \\ Bryme \\ Rps65 \\ \downarrow 2.03 \\ Transcription factor \\ Camk2a \\ \downarrow 2.17 \\ Oter \\ Oter \\ Sox11^* \\ \downarrow 2.5 \\ Oter \\ Sox11^* \\ Iat \\ Sox10^* \\ Oter \\ Sox10^* \\ Oter \\ Sox11^* \\ Iat \\ Sox10^* \\ Oter \\ Sox11^* \\ Oter \\ Sox11^* \\ Oter \\ Sox10^* \\ Oter$.0256	
Pdgfb* \downarrow 3.89LigandSox11* \downarrow 2.5.0134Transcription factorInsm1* \downarrow 20.7.009Transcription factorCdl6 \uparrow 2.387.009Transcription factorCll cycle/proliferationCcnb1ip \uparrow 32.47.19718EnzymesCdk6 \uparrow 2.53.10235Kinase/phosphataseFitg1* \uparrow 2.11.10235Kinase/phosphataseStat5b \uparrow 2.05.00464Transcription factorMmp14 \downarrow 2.02.021EnzymeRps6 \downarrow 2.03.17212Adaptor/regulatorHoxa3 \downarrow 2.17.07472Kinase/phosphataseTial1 \downarrow 2.22.0609Nucleotide bindingFoxp2* \downarrow 2.45.17anscription factorGil3 \downarrow 3.54.03856CytoskeletonIgals7 \downarrow 3.01.01206Cell adhesionGil3 \downarrow 3.54.03856Transcription factorFoxC1* \downarrow 3.73.0256Transcription factorRpL17 \downarrow 5.10235Adaptors/regulatorHeart morphogenesisIgals4 \uparrow 3.83.0671Kinase/phosphatase.0671Kinase/phosphataseCili3 \downarrow 3.54.03856Transcription factorNeural related genes.0256Transcription factorDifferentiationYwhag2.1.06031Adaptor/regulator.0256Transcription factorGil3 \downarrow 3.54.0256Transcription factorGil3 \downarrow 3.54.03856Transcr		Focal adhesion			0074	
$\begin{array}{c} Sox11^* \downarrow 2.5 \\ Insm1^* \downarrow 2.07 \\ Gja5^* \downarrow 23.87 \end{array} \begin{array}{c} 0.0134 \\ .009 \end{array} \begin{array}{c} Transcription factor \\ Transcription factor \\ Transcription factor \\ Transcription factor \\ Channel/transporter \end{array} \\ \begin{array}{c} Cell cycle/proliferation \\ Cytoskeleton \\ Cth 1ip \ 132.47 \\ Cdk6 \ 12.53 \\ Eif2ak1 \ 12.16 \\ Pttg1^* \ 12.11 \\ Stat5b \ 12.05 \\ Nmp14 \ 42.02 \\ Abstring \ 17212 \\ Adaptor/regulator \\ Hoxa3 \ 42.15 \\ Transcription factor \\ Camk2a \ 42.17 \\ Otag4 \ 17212 \\ Adaptor/regulator \\ Hoxa3 \ 42.15 \\ Transcription factor \\ Camk2a \ 42.17 \\ Otag4 \ 17212 \\ Adaptor/regulator \\ Hoxa3 \ 42.15 \\ Transcription factor \\ Sox11^* \ 42.5 \\ Otag4 \ 17212 \\ Adaptor/regulator \\ Hoxa3 \ 42.15 \\ Transcription factor \\ Sox11^* \ 42.5 \\ Otag4 \ 17212 \\ Adaptor/regulator \\ Nucleotide binding \\ Foxp2^* \ 42.45 \\ Transcription factor \\ Nucleotide binding \\ Foxp2^* \ 42.45 \\ Transcription factor \\ Nucleotide binding \\ Anxa6 \ 42.6 \\ Otag856 \\ Cytoskeleton \\ Gli3 \ 43.54 \\ Otag56 \\ Transcription factor \\ Nucleotide binding \\ Coll1a1 \ 42.01 \\ Adaptors/regulator \\ RpL17 \ 45 \\ Cli1a1 \ 42.26 \\ Otag56 \\ Transcription factor \\ Transcription factor \\ Transcription factor \\ Cell adhesion \\ Transcription factor \\ Transcription factor \\ Nucleotide binding \\ Coll1a1 \ 42.01 \\ Adam19^* \ 42.16 \\ NF-ATc2 \ 42.29 \\ Otag56 \\ Transcription factor \\ T$.0671	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			-		0124	•
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $						
Cell cycle/proliferationCytoskeletonCcnb1ip132.47 Cdk61.9718Enzymes Kinase/phosphatase Transcription factorPttg1*12.11 Stat5b1.0235Kinase/phosphatase Transcription factorStat5b12.05 Mmp14.00464 2.03Transcription factorMmp142.02 Ptg2*.0216Enzyme Rps6Hoxa32.15 2.15.15815Transcription factorCamk2a2.17 2.17.07472Kinase/phosphatase Hoxa3Tial12.22 4.245.0609Nucleotide binding Transcription factorSox11*2.25 4.245.0134Transcription factor Nucleotide binding Transcription factorGi33.54 4.255.0134Transcription factor Nucleotide binding Transcription factor Nucleotide binding Anxa6.0256 2.03856H3f3b 4.255.0256 4.373Transcription factor Transcription factor ToxC1* 4.373.0256 0.03856Heart morphogenesisItga4 NF-ATC2.0671 4.03856Cell adhesion Enzyme 0.03 Transcription factor Transcription facto					.009	
CytoskeletonCcnb1ip $\widehat{132.47}$ Cdk6 19718 Enzymes Kinase/phosphatase Eif2ak1Pttg1* $\widehat{2.16}$ $\widehat{10235}$ Kinase/phosphatase Transcription factorStat5b $\widehat{2.05}$ 0.0464 Transcription factorMmp14 2.02 021 EnzymeRps6 42.03 1.7212 Adaptor/regulatorHoxa3 42.15 1.5815 Transcription factorCamk2a 42.17 0.7472 Kinase/phosphataseTial1 42.22 0609 Nucleotide bindingFoxp2* 42.45 2.65 Nucleotide bindingAnxa6 42.6 0.3856 CytoskeletonLgals7 43.01 01206 Cell adhesionGli3 43.54 0.3856 Transcription factorFoxC1* 43.73 0.0256 Transcription factorRpL17 45 1.0235 Adaptor/regulatorHeart morphogenesisItga4 $\widehat{13.83}$ 0.0371 Heart morphogenesisItga4 $\widehat{13.83}$ 0.0671 Cell adhesionGli3 43.54 0.3856 Transcription factor 613 3.54 0.0356 Foxc1* 43.73 0.0256 Transcription factorRex 19748 1.373 0.0256 Transcription factor 613 4.354 0.3856 Transcription factor 613 4.324 0.3856 Transcription factor 1.722 Transcription factorFoxc1* $4.3.73$ 0.256 Transcripti			GjaJ	V23.07		channen/transporter
Cdk6 12.53 Eif2ak1Kinase/phosphataseEif2ak1 12.16 .10235Kinase/phosphatasePtig1* 12.11 Transcription factorStat5b 12.05 .00464Transcription factorMmp14 2.02 .021EnzymeRps6 42.03 .17212Adaptor/regulatorHoxa3 42.15 .15815Transcription factorCamk2a 42.17 .07472Kinase/phosphataseTial1 42.22 .0609Nucleotide bindingFoxp2* 42.45 Transcription factorSox11* 42.5 .0134Transcription factorSox11* 42.5 .0134Transcription factorGil3 43.54 .03856Transcription factorFoxC1* 43.73 .0256Transcription factorRpL17 45 .10235Adaptors/regulatorRpL17 45 .10235Adaptors/regulatorRpL17 45 .10235Adaptors/regulatorRpL17 45 .003Transcription factorGil3 43.54 .03856Transcription factorGil3 43.54 .03856Transcription factorFoxc1* 43.73 .0256Transcription factorGil3 42.61 .03856Transcription factorGil3 42.54 .03856Transcription factorFoxc1* 43.73 .0256Transcription factorCdi13 42.54 .03856Transcription factorFoxc1* 43.73 .0256 <td>Cell cycle/pr</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Cell cycle/pr					
Eif2ak1 12.16 $.10235$ Kinase/phosphatasePttg1* 12.11 Transcription factorStat5b 12.05 $.00464$ Transcription factorMmp14 2.02 $.021$ EnzymeRps6 42.03 $.17212$ Adaptor/regulatorHoxa3 42.15 $.15815$ Transcription factorCamk2a 42.17 $.07472$ Kinase/phosphataseTial1 42.22 $.0609$ Nucleotide bindingFoxp2* 42.45 Transcription factorSox11* 42.55 $.0134$ Transcription factorH3f3b 42.55 Nucleotide bindingAnxa6 2.6 $.03856$ CytoskeletonLgals7 43.01 $.01206$ Cell adhesionGli3 43.54 $.03856$ Transcription factorFoxC1* 43.73 $.0256$ Transcription factorRpL17 45 $.10235$ Adaptors/regulatorKhdrbs1 48.85 $.17212$ Nucleotide bindingHeart morphogenesisItga4 73.83 $.0671$ Cell adhesionEnzymeCell adhesionGi3 43.54 $.03856$ Transcription factorFoxc1* 43.73 $.0256$ Transcription factorGli3 43.54 $.03856$ Transcription factorGli3 43.54 $.03856$ Transcription factorHeart morphogenesisItga4 73.83 $.0256$ Neural related genes $.0671$ Cell adhesionDifferentiationYwhag<		Cytoskeleton	•		.19718	
Pttg1* $\uparrow 2.11$ Transcription factorStat5b $\uparrow 2.05$.00464Transcription factorMmp14 $\downarrow 2.02$.021EnzymeRps6 $\downarrow 2.03$.17212Adaptor/regulatorHoxa3 $\downarrow 2.15$.15815Transcription factorCamk2a $\downarrow 2.17$.07472Kinase/phosphataseTial1 $\downarrow 2.22$.0609Nucleotide bindingFoxp2* $\downarrow 2.45$ Transcription factorSox11* $\downarrow 2.5$.0134Transcription factorH373b $\downarrow 2.55$.0134Transcription factorNucleotide bindingNucleotide bindingNucleotide bindingAnxa6 $\downarrow 2.6$.03856CytoskeletonLgals7 $\downarrow 3.01$.01206Cell adhesionGli3 $\downarrow 3.54$.03856Transcription factorFoxC1* $\downarrow 3.73$.0256Transcription factorRpL17 $\downarrow 5$.10235Adaptors/regulatorKhdrbs1 $\downarrow 8.85$.17212Nucleotide bindingHeart morphogenesisItga4 $\uparrow 3.83$.0671Cell adhesionCili3 $\downarrow 3.54$.03856Transcription factorGia5* $\downarrow 22.8$.0031Transcription factorNeural related genesItferentiationYwhag $\uparrow 2.1$.06031DifferentiationYwhag $\uparrow 2.1$.06031Adaptor/regulatorNr4a2 $\downarrow 2.16$.043856Transcription factorNav1 $\downarrow 2.43$.0488CytoskeletonCili3 $\downarrow 2.20$ <t< td=""><td></td><td></td><td></td><td></td><td>10005</td><td></td></t<>					10005	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$.10235	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $					00464	•
Rps6 \downarrow 2.03.17212Adaptor/regulatorHoxa3 \downarrow 2.15.15815Transcription factorCamk2a \downarrow 2.17.07472Kinase/phosphataseTial1 \downarrow 2.22.0609Nucleotide bindingFoxp2* \downarrow 2.45Transcription factorSox11* \downarrow 2.5.0134Transcription factorH3f3b \downarrow 2.55Nucleotide bindingAnxa6 \downarrow 2.6.03856CytoskeletonLgals7 \downarrow 3.01.01206Cell adhesionGli3 \downarrow 3.54.03856Transcription factorFoxC1* \downarrow 3.73.0256Transcription factorRpL17 \downarrow 5.10235Adaptor/regulatorKhdrbs1 \downarrow 8.85.17212Nucleotide bindingHeart morphogenesisItga4 \uparrow 3.83Coll1a1Lga5* \downarrow 2.29.0671Cell adhesionEnzyme.0671Cell adhesionAdam19* \downarrow 2.16.0671Neural related genes.03856Transcription factorDifferentiationYwhag2.1.06031Netaz \downarrow 2.110Transcription factorKna26 \downarrow 2.0.1772Transcription factorNeural related genes.10611.06031DifferentiationYwhag2.1.06031Nav1.2.43.0488.04856Cli3.2.54.03856Transcription factorHeart morphogenesi.1772Transcription factorFoxc1*.2.71.06031Adaptor/regulator						
Hoxa3 \downarrow 2.15.15815Transcription factorCamk2a \downarrow 2.17.07472Kinase/phosphataseTial1 \downarrow 2.22.0609Nucleotide bindingFoxp2* \downarrow 2.45.0134Transcription factorSox11* \downarrow 2.5.0134Transcription factorH3f3b \downarrow 2.55.0126CytoskeletonLgals7 \downarrow 3.01.01206Cell adhesionGli3 \downarrow 3.54.03856Transcription factorFoxC1* \downarrow 3.73.0256Transcription factorRpL17 \downarrow 5.10235Adaptors/regulatorKhdrbs1 \downarrow 8.85.17212Nucleotide bindingHeart morphogenesisItga473.83Coll 1a1Heart morphogenesis.0671Cell adhesionEnzyme.0613.03856Transcription factorNeural related genes.03856Transcription factorDifferentiationYwhag2.1.06031Netaz.2.21.06031Adaptor/regulatorNr4a2.2.01.1772Transcription factorNav1.2.43.04886Transcription factorGli3.2.54.03856Transcription factorItgg2.2.880Transcription factor						5
Camk2a $\downarrow 2.17$.07472Kinase/phosphataseTial1 $\downarrow 2.22$.0609Nucleotide bindingFoxp2* $\downarrow 2.45$.0134Transcription factorSox11* $\downarrow 2.55$ Nucleotide bindingH3f3b $\downarrow 2.55$ Nucleotide bindingAnxa6 $\downarrow 2.65$.0134Lgals7 $\downarrow 3.01$.01206Cell adhesion.0133Gli3 $\downarrow 3.54$.03856FoxC1* $\downarrow 3.73$.0256FoxC1* $\downarrow 3.73$.0256RpL17 $\downarrow 5$.10235Adaptors/regulator.17212Khdrbs1 $\downarrow 8.85$.17212Nucleotide binding.0671Cell adhesion.0671Cell adhesion.0671Cell adhesion.0671Cell adhesion.0671Cell adhesion.0671Cell adhesion.0671Cell adhesion.0671Cell adhesion.0671Cell adhesion.0671Cell adhesion.0671Gli3 $\downarrow 3.54$.03856Transcription factorFoxc1* $\downarrow 3.73$.0256Transcription factorGi3 $\downarrow 3.54$.03856Transcription factorFoxc1* $\downarrow 3.73$.0256Transcription factorGi3 $\downarrow 3.54$.03856Transcription factorFoxc1* $\downarrow 3.73$.0256Transcription factorFoxc1* $\downarrow 3.73$.0256Transcription factorMarch $\downarrow 2.20$						
Tial1 $\downarrow 2.22$.0609Nucleotide binding Transcription factorFoxp2* $\downarrow 2.45$ Transcription factorSox11* $\downarrow 2.5$.0134Transcription factorH3f3b $\downarrow 2.55$ Nucleotide bindingAnxa6 $\downarrow 2.6$.03856CytoskeletonLgals7 $\downarrow 3.01$.01206Cell adhesionGli3 $\downarrow 3.54$.03856Transcription factorFoxC1* $\downarrow 3.73$.0256Transcription factorRpL17 $\downarrow 5$.10235Adaptors/regulatorKhdrbs1 $\downarrow 8.85$.17212Nucleotide bindingHeart morphogenesisItga4 $\uparrow 3.83$ Col11a1.0671Cell adhesionHeart morphogenesisItga4 $\uparrow 3.83$ Col11a1.0671Cell adhesionHeart morphogenesisNF-ATc22.29.003Transcription factorGli3 $\downarrow 3.54$.03856Transcription factorGli3 $\downarrow 3.54$.03856Transcription factorFoxc1* $\downarrow 3.73$ Col13.0256Transcription factorMr4a2 $\downarrow 2.16$ Cli3.06031Adaptor/regulatorNeural related genesVistag.06031Adaptor/regulatorDifferentiationYwhag $\uparrow 2.1$ Nr4a2.06031Adaptor/regulatorNr4a2 $\downarrow 2.11$ O.06031Adaptor/regulatorNav1 $\downarrow 2.43$ Al488.0488CytoskeletonGli3 $\downarrow 2.264$ Nav1.03856Transcription factorHard $\downarrow 2.01$ Nr4a2.03856Tra						
Foxp2* \downarrow 2.45Transcription factor Nucleotide bindingSox11* \downarrow 2.5.0134Transcription factor Nucleotide bindingH3f3b \downarrow 2.55.0134Transcription factor Nucleotide bindingAnxa6 \downarrow 2.6.03856CytoskeletonLgals7 \downarrow 3.01.01206Cell adhesionGli3 \downarrow 3.54.03856Transcription factorFoxC1* \downarrow 3.73.0256Transcription factorRpL17 \downarrow 5.10235Adaptors/regulatorKhdrbs1 \downarrow 8.85.17212Nucleotide bindingHeart morphogenesisItga4 \uparrow 3.83 Col11a1Cell adhesionCli3 \downarrow 3.54.0671Cell adhesionAdam19* \downarrow 2.16 Cli3.0671Cell adhesionNF-ATc2 \downarrow 2.29.003Transcription factorGi3 \downarrow 3.54.03856Transcription factorFoxc1* \downarrow 3.73.0256Transcription factorGi3 \downarrow 3.54.03856Transcription factorFoxc1* \downarrow 3.73.0256Transcription factorRoto* \downarrow 2.20.003Transcription factorFoxc1* \downarrow 3.73.0256Transcription factorHeart morphogenesis \downarrow 3.74.06031Adaptor/regulatorNF-ATc2 \downarrow 2.20.06031Adaptor/regulatorNta2 \downarrow 2.11.06031Adaptor/regulatorNta2 \downarrow 2.1.06031Adaptor/regulatorNta2 \downarrow 2.1.06031Adaptor/regulatorNta						
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$					10000	0
H3f3b $\downarrow 2.55$ Nucleotide bindingAnxa6 $\downarrow 2.6$.03856CytoskeletonLgals7 $\downarrow 3.01$.01206Cell adhesionGli3 $\downarrow 3.54$.03856Transcription factorFoxC1* $\downarrow 3.73$.0256Transcription factorRpL17 $\downarrow 5$.10235Adaptors/regulatorKhdrbs1 $\downarrow 8.85$.17212Nucleotide bindingHeart morphogenesisItga4 $\uparrow 3.83$ Cell adhesionColl 1a1 $\downarrow 2.01$.0671Cell adhesionAdam 19* $\downarrow 2.16$.0671Cell adhesionNeural related genesU.06631Adaptor/regulatorDifferentiationYwhag2.1.06031Adaptor/regulatorNr4a2 $\downarrow 2.11$ 0Transcription factorHey1 $\downarrow 2.0$.1772Transcription factorHay1 $\downarrow 2.43$.0488CytoskeletonGli3 $\downarrow 2.54$.03856Transcription factorHey1 $\downarrow 2.8$.04856Cytoskeleton					.0134	•
Lgals7 \downarrow 3.01.01206Cell adhesionGli3 \downarrow 3.54.03856Transcription factorFoxC1* \downarrow 3.73.0256Transcription factorRpL17 \downarrow 5.10235Adaptors/regulatorKhdrbs1 \downarrow 8.85.17212Nucleotide bindingHeart morphogenesisItga4 \uparrow 3.83Col11a1 \downarrow 2.01.0671Adam 19* \downarrow 2.16EnzymeNF-ATc2 \downarrow 2.29.003Transcription factorGli3 \downarrow 3.54.03856Transcription factorFoxc1* \downarrow 3.73.0256Transcription factorGli3 \downarrow 3.54.03856Transcription factorFoxc1* \downarrow 3.73.0256Transcription factorMeural related genesUU.06031Adaptor/regulatorDifferentiationYwhag \uparrow 2.1.06031Adaptor/regulatorNr4a2 \downarrow 2.110Transcription factorHey1 \downarrow 2.0.1772Transcription factorHey1 \downarrow 2.0.1772Transcription factorHey1 \downarrow 2.8.03856Transcription factor				↓2.55		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			Anxa6	↓2.6	.03856	Cytoskeleton
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			Lgals7	↓3.01	.01206	Cell adhesion
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			Gli3	↓3.54	.03856	Transcription factor
Khdrbs1 \downarrow 8.85.17212Nucleotide bindingHeart morphogenesisItga4 \uparrow 3.83 Col11a1.0671Cell adhesion EnzymeAdam 19* \downarrow 2.16 NF-ATc2.0671Cell adhesion EnzymeOG13 \downarrow 3.54.03856Transcription factor Transcription factor Channels/transporterNeural related genesYwhag \uparrow 2.1 Nr4a2.06031DifferentiationYwhag \uparrow 2.1 Hey1.06031Nav1 \downarrow 2.43 Otskeleton.04886 Transcription factor Transcription factor Transcription factorNav1 \downarrow 2.43 Otskeleton.04886 Transcription factor Transcription factor Transcription factor					.0256	
Heart morphogenesisItga4 \uparrow 3.83 Coll1a1 \downarrow 2.01 \downarrow 2.01 Adam19* \downarrow 2.06 \downarrow 2.16 NF-ATc2 \downarrow 2.09 \downarrow 2.29 Gli3 \downarrow 3.54 \downarrow 3.73 \downarrow 23.87 \downarrow 003 Transcription factor Transcription factor Granscription factor Channels/transporterNeural related genesDifferentiationYwhag Yu42 \uparrow 2.1 V2.11 \downarrow 06031 Transcription factor Channels/transporterNeural related genesTranscription factor Transcription factorNeural related genes0Differentiation Hey1 \downarrow 2.0Neural related genes0Differentiation Hey1 \downarrow 2.0Nav1 \downarrow 2.43 .03856Gli3 \downarrow 2.54 .03856Transcription factor Transcription factor Transcription factorTigf2 \downarrow 2.8 .0			•			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			Khdrbs1	↓8.85	.17212	Nucleotide binding
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Heart morp	hogenesis				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	r		Itga4	13.83		Kinase/phosphatase
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			Col11a1	↓2.01	.0671	Cell adhesion
Gli3J3.54 J3.73 Gja5*.03856 J23.87Transcription factor Transcription factor Channels/transporterNeural related genes.06031Adaptor/regulator Transcription factor Channels/transporterDifferentiation PifferentiationYwhag Nr4a2^2.1 J2.11.06031Adaptor/regulator Transcription factor Transcription factor Hey1Nav1 Gli3J2.43 J2.54 Tgif2.0488 J2.86Cytoskeleton						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			NF-ATc2	↓2.29	.003	Transcription factor
Gja5*J23.87Channels/transporterNeural related genesDifferentiationYwhag^12.1.06031Adaptor/regulatorNr4a2J2.110Transcription factorHey1J2.0.1772Transcription factorNav1J2.43.0488CytoskeletonGli3J2.54.03856Transcription factorTgif2J2.80Transcription factor			Gli3	↓3.54	.03856	Transcription factor
Neural related genes Ywhag 12.1 .06031 Adaptor/regulator Differentiation Ywhag 12.1 0 Transcription factor Nr4a2 J2.11 0 Transcription factor Hey1 J2.0 .1772 Transcription factor Nav1 J2.43 .0488 Cytoskeleton Gli3 J2.54 .03856 Transcription factor Tgif2 J2.8 0 Transcription factor					.0256	
DifferentiationYwhag↑2.1.06031Adaptor/regulatorNr4a2↓2.110Transcription factorHey1↓2.0.1772Transcription factorNav1↓2.43.0488CytoskeletonGli3↓2.54.03856Transcription factorTgif2↓2.80Transcription factor			Gja5*	↓23.87		Channels/transporter
DifferentiationYwhag↑2.1.06031Adaptor/regulatorNr4a2↓2.110Transcription factorHey1↓2.0.1772Transcription factorNav1↓2.43.0488CytoskeletonGli3↓2.54.03856Transcription factorTgif2↓2.80Transcription factor	Neural relat	ed genes				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			Ywhag	12.1	.06031	Adaptor/regulator
Hey1↓2.0.1772Transcription factorNav1↓2.43.0488CytoskeletonGli3↓2.54.03856Transcription factorTgif2↓2.80Transcription factor			-			
Gli3↓2.54.03856Transcription factorTgif2↓2.80Transcription factor			Hey1	↓2.0	.1772	
Tgif2 ↓2.8 0 Transcription factor			Nav1	↓2.43	.0488	
			Gli3		.03856	Transcription factor
Prph 46.41 0 Cytoskeleton			0			
Cytosketeton			Prph	↓6.41	0	Cytoskeleton

*Expression verified by qRT-PCR of FACS-isolated ROSA-YFP cardiac neural crest. For the ChIP-on-chip the false discovery rate (FDR) is presented. Each reported interval is considered significant and indicative of a potential binding site. Within the three confidence levels, FDR \leq .05 represents the highest confidence level; FDR \geq .05 \leq .1 is the second highest confidence level and FDR \geq .1 \leq .2 is the lowest confidence level where binding remains statistically significant. The primary data for the heart micro-arrays is available at the NIH microarray consortium website http://np2.ctrl.ucla.edu/np2/home.do. To navigate to the data, click on the "navigate repository" button and write Howard under investigator and click *go*. The project will come up and the data can be accessed by clicking on the magnifying glass.

(Table 2; Fig. 7). Based on ChIP (Cx40) or ChIP-on-chip we identified a number of putative Hand2-target genes. We analyzed Cx40 in some detail because Cx40 null mice display membranous VSDs phenotypically similar to those occurring in our *Hand2*-loss-of-function embryos (Kirchhoff et al., 2000) and we found that Cx40 is expressed in cardiac neural crest cells (Fig. 6). A putative *cis*-regulatory region for the Cx40 gene has been previously identified

(Seul et al., 1997) and spans bases from -1190 to +121. Initially, we analyzed this region for E-box (bHLH consensus) binding sites (CANNTG) and identified a total of 9 sites 5' to the Cx40 transcription start site 5' to exon 1 (Fig. 7A). For ChIP analysis we used H9c2 cells, a rat cardiomyocyte cell line which endogenously expresses Hand2 (Zang et al., 2004) and which up-regulates Cx40 expression in response to Hand2 overexpression (Togi et al., 2006). PCR amplification of DNA fragments immunoprecipitated using our Hand2 antibody revealed that DNA fragments overlapping the proximal (-655 to)-283 bp), but not distal (-1144 to -814 bp) E-box-containing DNA sequences co-immunoprecipitated with Hand2 (Fig. 7B); the two sets of primers we designed and tested flank all 9 of the E-boxes in the Cx40 5' putative cis-regulatory region. The PCR product band was TOPO® cloned (Invitrogen, Carslbad, CA) and the sequence verified as the appropriate region of Cx40 (not shown). These data suggest that Hand2 directly binds to the putative Cx40 promoter at E-box sites located between -655 and -283 bp relative to the transcription start site. In order to directly demonstrate that this binding could have functional relevance, we conducted trans-activation studies to confirm that Hand2 can regulate Cx40 transcriptional activity. We used a reporter construct (generously provided by Benoit Bruneau, Gladstone Institute of Cardiovascular Disease) containing sequence corresponding to bases -1068 to +121 of the Cx40 gene, that drives expression of a luciferase cassette (Bruneau et al., 2001); this was cotransfected with Hand2 and/or E12 expression constructs into HEK 293 cells (Fig. 7C). While expression of neither Hand2 nor E12 alone was sufficient to modulate Cx40-luc reporter expression, expression of both factors together up-regulated Cx40-luciferase activity (~2.2 fold) over baseline (P<.001). These results indicate that Hand2 and its bHLH dimer partner, E12, can positively regulate gene expression from the Cx40 promoter. Together, these results indicate that Cx40 is a direct target of Hand2 within the cardiac neural crest.

We validated (qRT-PCR) an additional subset of genes, identified in the array screen, that appear in one or more of the functional pathways associated with cell-cell interaction and/or adhesion (Table 2; validated genes are shown in blue). In addition to qRT-PCR and ChIP, we also performed a ChIP-on-chip screen on FACsorted cardiac neural crest-derived cells (Table 2) to determine which of the validated genes are potentially neural crest-specific Hand2 direct transcriptional targets.

Genes associated with neural crest cell cycle

We validated a subset of genes associated with cell cycle because of the significant reduction in proliferation that we observe (Fig. 4) when Hand2 is deleted in neural crest-derived cells (Hendershot et al., 2008). The genes that we validated, based on qRT-PCR and ChIP-onchip, include cdk6 (12.53), Insm1 (120.7 array vs. undetectable qRT-PCR); each of these genes is associated with some aspect of cell proliferation and/or known Hand2-related genes. Several classical "cell cycle" genes are differentially regulated in the absence of Hand2. The most highly regulated gene in the array was cyclin B1 interacting protein 1 (Ccnb1ip1; 137.42). The protein coded for by this gene is a Ring finger protein. It is a member of a group of B-type cyclin E3 ubiquitin ligases that also has cyclin-dependent kinase and cyclindependent phosphorylation sites (Toby et al., 2003). This protein interacts with cyclin B1, an important checkpoint regulator of cell cycle progression, and causes its degradation (Toby et al., 2003). Overexpression of Ccnb1ip1 substantially reduces expression of cyclin B1 resulting in decreased proliferation (Toby et al, 2003). This protein also has been shown to affect migration and metastasis (Singh et al., 2007) potentially linking cell cycle with migration; functions which are both effected by deletion of Hand2. It is interesting to note that none of the cyclin proteins was identified in our array but several cyclin-dependent kinases or interacting proteins were. Cyclin dependent kinase 6 (12.53) was increased. Cyclin dependent kinase 6 is a




Fig. 6. Connexin 40 expression is decreased by targeted deletion of *Hand2* in the neural crest. Expression of connexin 40 was examined in the outflow tract of *Hand2^{wt/wt;Wnt1-Cre;R26R/YFP* [A, C, E] and *Hand2^{R1/det;Wnt1-Cre;R26R/YFP* [B, D, F] E10.5 cryostat sections encompassing the entire outflow tract. Tissue sections (20 µm) were immuno-labeled for expression of YFP (reporter, green) and connexin 40 (red). The entire outflow tract was imaged at 20× and 63×; .5 µm optical sections were compressed in the z-plane and assessed. Ten pairs of matched sections were examined. The majority of neural crest-derived cells migrating within the outflow tract with neighboring cells. In *Hand2* mutant embryos, only a few neural crest-derived cells maintain expression of connexin 40 (B, D, E]; the expression pattern appears normal in those few cells that maintain connexin 40. The arrows point to connexin 40 expressed in the myocardium. Abbreviation: Cx40 (connexin 40).}}

serine/threonine protein kinase that is activated by cyclin D1, D2 and D3, and which is required for the G0 to G1 transition (Malumbres and Barbacid, 2005). Additional genes coding proteins that have a role in cell cycle regulation were also identified. Insm1 (Insulinoma associated 1) was of particular interest because it has been identified as a member of a transcription factor network that regulates development of neural crest-derived noradrenergic sympathetic ganglion neurons (Howard, 2005; Hendershot et al., 2008; Wildner et al., 2008; Parlier et al., 2008). Hand2 has a central role in this pathway and likely functions upstream or in parallel with Insm1 (Hendershot et al., 2008; Lan and Breslin, 2009). Targeted deletion of Hand2 or Insm1 results in a marked decrease in proliferation of the pool of neural precursor cells (Hendershot et al., 2008; Wildner et al., 2008). A potential site of Insm1 activity in the heart is at cyclin D1. Insm1 binds to cyclin D1 (Liu et al., 2006) which competes for the interaction of cyclin D1 with Cdk4. The Cdk4/cyclin D1 interaction is required for proper phosphorylation of retinoblastoma protein Prb necessary for cell cycle progression from G0 to G1 (Zhang et al., 2009). The putative Insm1 interacting protein, CAP1 (adenylate cyclase associated protein; Xie et al., 2002) transcript level was also increased $(\uparrow 7.21)$ in the mutant hearts. Interestingly, transcripts encoding peripherin, a neuron specific gene and associated with Hand2 and Insm1 was down-regulated 6.41 fold in the mutant hearts. Expression of several histones was also affected by deletion of Hand2 including: 1) histone cluster 1 (12.1; Hist1h2bb); 2) H2a histone family member $V(\downarrow 2.27)$; 3) H3 histone family 3B ($\downarrow 2.55$); and 4) histone cluster 2 H2be (\downarrow 2.67). Although the nucleosome (core histone complex) is associated with multiple aspects of DNA replication, repair and chromatin structure, one of these histones, H2be, is required for Cdk6 to bind its substrate, retinoblastoma protein Prb, required for initiation of cell cycle progression from G to S phase (Zhao et al., 2000; Marzluff et al., 2002; Jaeger et al., 2005; Ewen, 2009). Although we found a significant reduction in cell proliferation (Fig. 4G), there is no significant reduction in the percentage of cells that initiate mitosis (Fig. 4H) suggesting a potential role for Hand2 in regulation of cell cycle progression.

Genes associated with VSD and DORV

A number of genes have been identified as risk loci for VSDs and DORV. We were very interested in these genes since targeted deletion of *Hand2* in the neural crest results in these defects in 100% of embryos examined (Fig. 2). *Sox11* (\downarrow 2.5), a member of the SRY-related HMG-box family of transcriptional regulatory genes is an important regulatory gene affecting neural, skeletal and cardiac development. *Sox11* null embryos develop VSDs with 100% penetrance (Sock et al., 2004). These embryos also display DORV and other OFT defects similar




Fig. 7. Connexin 40 is a direct Hand2-target gene. [A] Schematic representation of the Eboxes (consensus: CANNTG) located within genomic region 5' to Exon 1 (Exl) of the *Cx40* gene. Amplicons of the distal (Cx40 [-1144 to -814]) and proximal (Cx40 [-655 to -283]) primer sets (arrows) used for ChIP assays are denoted. [B] ChIP using a Hand2-specific antibody co-immunoprecipitates DNA fragments overlapping the proximal (Cx40 [-655 to -283]), but not distal (Cx40 [-1144 to -814]), primer sets, indicating that Hand2 binds to the *Cx40* promoter within this region. [C] Luciferasereporter transactivation assays in HEK 293 cells show that Hand2 and E12 cooperatively up-regulate expression of a *Cx40*-luciferase reporter (Cx40-pX2P) ~2.2 fold over baseline (n=3, P<.001). Individually, Hand2 and E12 do not significantly influence *Cx40*-pX2P expression.

to that which we observe in the Hand2 mutant embryos. Gli3 (\downarrow 2.54; C2H2-type zinc finger protein) was identified as a VSD susceptibility gene in a study focused on 12q13 chromosomal region previously identified as associated with occurrence of VSD in humans (Qui et al., 2006). Although the molecular mechanism of Gli function in the cardiac neural crest is not yet known, Gli-family members mediate sonic hedgehog (Shh) signaling (te Welscher et al., 2002a,b; Stamataki et al., 2005) and Zic3 translocation to the nucleus appears dependent upon Gli3 (Bedard et al., 2007). Disruption of Zic3 expression results in a number of developmental defects related to left-right asymmetry including conotruncal malformations (Mégarbané et al., 2000; Ware et al., 2006). Mutations in Foxc1 (13.73; forkhead-winged helix transcription factor family) are associated with abnormal vasculogenesis, coarctation of the aortic arch, and VSDs, related to Notch signaling (Kume et al., 2001; Seo et al., 2006); the only linkage to Notch signaling in our array is Hey1 (12.0). Notch signaling has been implicated as important for septation and Hey 1 (hairy and enhancer of split-related family of bHLH-type transcriptional repressor) is a Notch-downstream target gene (Sakata et al., 2002). In conjunction with Hey 2 (not regulated) Hey 1 has been implicated in Notch-mediated epithelialmesenchymal transition (EMT) (Fischer et al., 2004; Niessen and Karsan, 2008). This occurs via a decrease in expression of several metalloproteinases (MMP; Brou et al., 2000). Two MMPs, MMP14 $(\downarrow 2.02)$ and Adam 19 $(\downarrow 2.16)$ were down-regulated in response to deletion of Hand2 in the cardiac neural crest suggesting that the reduction in migration and invasion of the cardiac cushions could be related to decreased expression of these genes.

Valvulogenesis

The cardiac cushions develop in the distal portion of the common OFT and between the common atria and ventricle (reviewed in Barnett and Desgrosellier, 2003; Goodwin et al., 2005). Cushion formation requires production of extracellular matrix material that becomes situated between the endocardial and myocardial layers of the developing heart. Neural crest-derived cells contribute to the truncal cushions that eventually form the aorticopulmonary septum and semilunar valves (de Lange et al., 2004). A number of genes associated with aspects of cardiac cushion formation, valvulogenesis and/or septation have been identified and which are affected by targeted deletion of Hand2 in the neural crest. In the absence of *Nf-ATc* (nuclear factor of activated T-cells) heart valves fail to form and embryos die (de la Pompa et al., 1998; Zhou et al., 2002). Expression of NF-ATc1 is induced by NF-ATc2 $(\downarrow 2.29)$ that is down-regulated in response to Hand2-deletion in the neural crest. Collagen type XI a1 (Col11a1, 12.1 array vs. 11.43) PCR) is expressed in the non-cartilaginous tissue of the heart. Mutations in the Col11a1 gene have been implicated in valve defects. Adam 19 (12.16 array vs. 12.63 qRT-PCR) is a metalloprotease that is expressed in the endocardial cushion. Adam 19 null mice die within a week of birth due to thickened and misshapen semilunar valves, tricuspid valves, and membranous VSD (Horiuchi et al., 2005; Komatsu et al., 2007). EMT is required for proper cardiac cushion transformation (Barnett and Desgrosellier, 2003) and is stimulated by members of the transforming growth factor- β family of proteins. Deletion of latent transforming growth factor beta binding protein 1 (Ltbp1, 12.13) results in multiple heart defects including improper septation of the OFT, patent truncus arteriosus (PTA), and interrupted aortic arch (IAA) (Todorovic et al., 2007).

Discussion

The consequences to loss of *Hand2* in the heart have been a focus of much investigation (Srivastava et al., 1997; Yamagishi et al., 2001; McFadden et al., 2005; Morikawa and Cserjesi, 2008; Reviewed in

Firulli and Thattaliyath, 2002; Firulli, 2003; Bhattacharya et al., 2006; Olson, 2006; Srivastava, 2006). Hand2 contributes to normal development of both the OFT and right ventricular myocardium. Cells from the secondary heart field and cardiac neural crest contribute to the OFT by migrating into the formed heart tube, whereas only secondary heart field cells contribute to right ventricle myocardium development (reviewed in Kelly and Buckingham, 2002; Garry and Olson, 2006; Hutson and Kirby, 2007). Since Hand2 is expressed within the second heart field myocardium and cardiac neural crest it has been difficult to separate effects of Hand2 deletion in neural crest-derived or mesoderm-derived components of the heart because of the close interaction of cells from these two lineages. This problem has been addressed in the current studies. We employed an intercross of our mice harboring a Hand2 conditional allele with the Wnt1-Cre transgenic mouse line to interrogate the consequences to loss of Hand2 specifically in the neural crest. Our analysis of OFT development combined with gene profiling data demonstrates that Hand2target genes fall into a variety of functional categories including cell adhesion, cell cycle regulation, proliferation control and intracellular signaling. We have identified a large number of genes as likely or identified loci for neural crest-dependent cardiac developmental anomalies, including VSD, DORV, and valve malformation.

Hand2 gene dosage and cardiac development

Conditional inactivation of Hand2 in secondary heart field cells presages malformation of the right ventricle manifesting as ventricular hypoplasia and in the conotruncus resulting in membranous ventricular septal defects (VSDs. Specific deletion of Hand2 in neural crest-derived cells that contribute to the conotruncus results in developmental abnormalities expected based on expression pattern. Interestingly, occurrence of OFT anomalies and VSDs was not predicted to be prevalent in Hand2^{fl/fl;Wnt1-Cre} embryos because of potential redundant function with Hand1, which is co-expressed with Hand2 in a subset of cardiac neural crest cells (McFadden et al., 2005). Deletion of Hand1 in neural crest-derived cells does not affect phenotypically, embryonic development. However, in these same mice, Hand2 haploinsufficiency, due to deletion in the ventrolateral branchial arch, shows novel defects in cranio-facial neural crestderived structures (Yanagisawa et al., 2003; Barbosa et al., 2007). We observe clear defects in the cardiac neural crest of Hand2^{fl/fl;Wnt1-Cre} embryos, where Hand1 is co-expressed, suggesting that Hand2 function would be dominant to that of Hand1; these closely related transcriptional regulators do not appear to have redundant functions related to migration or differentiation of cardiac neural crest. Our data suggest that Hand1 and Hand2 have unique functions in the cardiac neural crest.

The defect we observe in right ventricle development in the Hand2 hypomorph embryos, disorganized trabeculations and thin ventricular wall, was predictable given that Hand1 expression is low (albeit undetectable) within the right ventricle. The phenotypic characteristics we describe in both Hand2fl/fl;Wnt1-Cre and Hand2flneo/flneo embryos supports previous data suggesting that Hand2 protein function is dosage dependent (McFadden et al., 2005; Firulli et al., 2005; Hendershot et al., 2008). The phenotype observed in the Hand2 hypomorph embryos compared to loss of Hand2 in neural crestderived cardiac structures underscores the complex functional interactions that the Twist family of bHLH proteins exhibits in-vivo (Firulli et al, 2003, 2005; Barnes and Firulli, 2009); our data indicate a complex pattern of interaction between different cell types that express Hand2. The nature of the defects we observe in both the Hand2 hypomorph embryos and Hand2 neural crest-specific knockout embryos attests to the utility of our genetic model. Because of the acknowledged importance of gene dosage in Hand factor function, the Hand2 hypomorph allele will provide a valuable tool for future examination of phenotypic response to misexpression of Hand2

as well as genetic and functional interaction of Hand2 with other transcriptional regulators.

Outflow tract defects

In the mouse, formation of the septum and valves initiates between E9.5 and E10 (Webb et al., 1998; Jiang et al., 2000). Cells in the OFT undergo an EMT and migrate into the cardiac jelly (Song et al., 2000; Camenisch et al., 2002; Gitler et al., 2003; Person et al., 2005); these cells derive from the neural crest and the endocardium (Runyan and Markwald, 1983; Camenisch et al., 2000; Kisanuki et al., 2001). In conjunction with cells located in the AV canal (endocardial origin), neural crest-derived cells will form the membranous septum and valves (Runyan and Markwald, 1983, Poelmann et al., 1998; De Lange et al., 2004). Formation of the aorticopulmonary septation complex involves neural crest-derived cells and non-neural crest-derived cells in the conotruncal ridges (Waldo et al., 1998). Neural crest-derived cells form the prongs of the aorticopulmonary septum at around E9.5 (Waldo et al., 1998, 1999; Kisanuki et al., 2001); these prongs of cells eventually form parts of both the aorta and pulmonary structures, valves and arterial smooth muscle (Waldo et al., 1998). Our results indicate that formation of the AP prongs is affected by loss of Hand2 in the neural crest-derived cells that migrate into the OFT. The reduced cell density and apparent decrease of cell-cell contact between the migrating cells is reflected in altered expression of a number of genes associated with these functions.

Formation of the OFT septum begins at around E10.5 (Jiang et al., 2002). The defects that we observe in septation and OFT vessel formation likely result from a substantial reduction in the number of neural crest-derived cells that form the AP prongs. At E9.5 neural crest-derived cells are located proximal to the aortic sac and initiating migration through it to the truncus arteriosus (Jiang et al., 2002). Later in development, the OFT will form the aortic and pulmonary OFT vessels as the aorticopulmonary septum forms at the distal pole and the conotruncal septum forms at the proximal end. The outflow valves form concurrently. Our results demonstrate that Hand2 is required for these morphogenetic events to proceed properly. As described previously (Morikawa and Cserjesi, 2008), the absence of Hand2 in cardiac neural crest causes misalignment of the aortic arch arteries and OFT. Our data suggest that cell-cell communication, mediated by gap junctions, constitutes a critical component of signaling in the cardiac neural crest; anomalies in vessel alignment and septation appear to occur, in part, as a result of decreased expression of Cx40 in neural crest-derived cells. The reduction in Cx40 expression appears to be a direct result of Hand2 loss-of-function since our data indicate that Cx40 is a direct target of Hand2.

Cell-cell contact and intercellular signaling via gap junctions have been associated with cell cycle control (Lowenstein, 1988) and neural crest migration (Huang et al., 1998; Lo et al., 1997). Both gain-offunction of connexin 43 in the neural crest and systemic loss-offunction of connexin 43 results in defective development of the conotruncus as well as the pulmonary outflow vessel (Reaume et al., 1995; Ewart et al., 1997; Huang et al., 1998; Sullivan et al., 1998; Simon et al., 2004). It is clear from these previous studies that expression levels of connexin proteins in the neural crest is critical and contributes to development of the OFT; Cx40 has not previously been reported in the neural crest. Importantly, it appears that Hand2 directly affects expression of Cx40 in the developing OFT. It will be interesting in future studies to validate other Hand2 targets or interacting molecules identified in our mRNA screen and validated as potential direct Hand2 targets in out ChIP-on-chip screen that are involved in cell-cell contact and migration in OFT formation. Based on our gene profiling, expression of connexin 43 was not altered by deletion of *Hand2* in the neural crest. We provide evidence that in the absence of Hand2, neural crest-derived cells migrating within the OFT do not migrate as a coherent sheet of cells as they normally do (Bancroft and Bellairs, 1976; Davis and Trinkaus, 1981; Raible and Eisen, 1996; Gammill et al., 2006; Kuriyama and Mayor; 2008). It is interesting to note however, that the extent of migration is not adversely affected by *Hand2* deletion. Although we did not detect any notable difference in the length of the OFT in *Hand2* mutant embryos, the apparent reduction in the numbers of neural crest-derived cells coupled with the decreased adhesion that we observe in the AP prongs suggests that it is aberrant remodeling affecting proper generation of the aorticopulmonary septation complex that contributes to generation of DORV and VSD.

Interestingly, in about 20% of the hearts that we examined, we found neural crest-derived cells that had tracked incorrectly and migrated into the ventricles. Although we did not observe any apparent effect of these mis-located neural crest-derived cells on ventricle development, abnormal ventricle development has been reported previously using an independently derived line of floxed Hand2 mice (Morikawa and Cserjesi, 2008). These authors concluded that loss-of-Hand2 function in cardiac neural crest induced proliferation of cardiomyocytes resulting in enlarged right ventricles (Morikawa and Cserjesi, 2008). This was an intriguing finding because neural crest-derived cells do not normally contribute to myocardial development although expression of Hand2 in cardiomyocytes is necessary for right ventricle development (Srivastava et al., 1997). The hypertrabeculations observed in these mutant hearts is reminiscent of what we observe in our Hand2 hypomorphic embryos. It is likely that this reported aberrant right ventricle development was in fact a primary hypomorphic phenotype within the cardiomyocytes, as this group observed hypomorphic phenotypes from their floxed Hand2 mice (Morikawa et al., 2007); in these embryos, although targeted Hand2 deletion in the neural crest would give rise to the expected defects in OFT development, misexpression of Hand2 in the right ventricle would be expected to affect trabeculations and cell cycle.

Neural crest cell cycle regulation

In the peripheral nervous system Hand2 is required for neurogenesis and neurotransmitter specification and expression in noradrenergic sympathetic ganglion neurons (Howard et al., 1999, 2000; Wu and Howard, 2002; Xu et al., 2003; Hendershot et al., 2007, 2008; Morikawa et al., 2007; Schmidt et al., 2009). One important function of Hand2 is in cell cycle regulation; in the absence of Hand2 neural precursor cells cease to divide (Hendershot et al., 2008). We identified a number of cell cycle and proliferation genes regulated downstream of Hand2 in the heart. The number of cells that populate the OFT is reduced following targeted deletion of Hand2 in the neural crest; this could occur as a result of aberrant migration, decreased proliferation and/or abnormal cell cycle regulation; gene profiling suggests that all of these events are affected in the mutant hearts. The appropriate number of cells in the AP prongs of neural crest-derived cells that move into the truncal cushions is required for elongation of the conotruncus and septation into the aortic and pulmonary trunks. The abnormal pattern of migration, decreased cell numbers and loss of cell-cell signaling likely contribute to the formation of VSDs observed in all mutant embryos. Normal closure of the membranous septum involves three coordinated morphogenetic events: the muscular septum must grow upwards, the endocardial cushions must form the inlet septum (AV canal) and the formation of outlet septum by growth of the conotruncal ridges must occur (Webb et al., 1998; Lamers and Mooreman, 2002; Raid et al., 2009). As part of this fusion, the valves are also formed. We observed in 100% of mutant embryos DORV that may have developed as a consequence of the development of VSD (Yelbuz et al., 2002; Xu et al., 2004) or due to the misalignment of the great vessels (described in Morikawa and Cserjesi, 2008) observed in embryos with neural crest targeted deletions of Hand2. Abnormal development of the cardiac cushions could contribute to the generation of these defects. Mis-regulation of transit through the

cell cycle, resulting in a decreased number of neural crest-derived cells populating the AP prongs likely affects truncal cushion development and septation. Based on the profile of Hand2-trancriptioanl targets and the array of proliferation/cell cycle genes modulated by loss of Hand2, we suggest that the cell cycle is arrested/delayed in G1 or S phase, a situation that would account for a reduction in cells while maintaining a stable proportion of cells in M phase.

Cardiac cushion and valve development

Proper patterning and differentiation of the cardiac cushions are required for formation of the semilunar valves and aorticopulmonary septation. In order for the cardiac cushions to develop extracellular matrix must be deposited into the acellular cardiac jelly. In order for valves to form, EMT must occur to remodel the cushions (Wang et al., 2004). Genes associated with transcriptional control (Nf-ATc; Foxc1, Foxp1), extracellular matrix composition (collagen XI a1; Ltbp1) and protein modifying enzymes (metalloproteases), all associated with aspects of cardiac cushion development, were affected by deletion of Hand2; a number of these genes are likely direct Hand2 targets. The cardiac phenotype of mouse embryos deficient in Nf-ATc, FoxP1, and Sox11 show nearly identical defects resulting from problems in cardiac cushion development (de la Pompa et al., 1998; Ranger et al., 1998; Kume et al., 2001; Wang et al., 2004; Sock et al., 2004). Previously none of these genes has been associated with Hand2. Hand2 is a BMP-downstream target (Howard et al., 2000; Liu et al., 2005b). BMP is an important signaling molecule regulating aspects of OFT development including cushion transition and valvulogenesis (reviewed in Délot, 2003; Jia et al., 2007).

Generation of VSD and DORV

Conditional targeted deletion of Hand2 in the neural crest resulted in DORV with associated VSD with 100% penetrance. Additionally, we identified a number of Hand2-target genes correlated with or identified as susceptibility loci for VSD and/or DORV (Zhang et al., 2006). We identified Gli3 as a direct Hand2 target and whose expression is significantly reduced as a consequence to loss of Hand2 in cardiac neural crest. The decreased expression of Gli3 is of interest as Gli3 has been identified as a susceptibility locus for VSD (Qui et al., 2006) and is associated with Hand2 expression and function in the developing limb bud (te Welscher et al., 2002a,b; Liu et al., 2005a; Barnes and Firulli, 2009). Gli3 represses sonic hedgehog (SHH), a signaling molecule associated with second heart field development but not associated with OFT morphogenesis (Dyer and Kirby, 2009). Sox11 is another gene associated with DORV and VSD (Sock et al., 2004) that we identified as a direct Hand2 target and which is down-regulated in the neural crest in response to deletion of Hand2. A number of genes regulated in response to deletion of Hand2, which we showed to be direct Hand2 targets and regulated in the neural crest, (Hey1, Foxc1, Mmp14) are related to the Notch signaling pathway. Notch signaling is implicated in migration and development of the cardiac cushions. Expression of *Hand2* in neural crest-derived neural precursor cells down-regulates expression of Hes1 (Howard unpublished result); Hey 1 is regulated in the cardiac neural crest. This intriguing result raises the possibility of identifying networks of Hand2-target genes that affect cell cycle and cell-cell contact in a number of differentiating cell types but which together mediate morphogenetic movements, proliferation and differentiation.

The constellation of birth defects associated with disrupted development of the OFT appears to represent a common phenotype susceptible to multiple sites of regulation. The results of our gene profiling have identified *Hand2* as a critical transcriptional regulatory factor that directly or indirectly impacts expression of genes associated with all aspects of OFT development. Given the complexity of OFT morphogenesis and the role Hand2 plays in multiple cell

lineages that contribute to its formation, our studies add insight into the cell autonomous neural crest contributions to OFT morphogenesis.

Acknowledgments

The authors would like to thank Janet Lambert, Jennifer Duerr and Sean Eringer for excellent technical assistance. We thank Dr. Phyllis Pugh for her assistance with the initial analysis of the gene microarray data. We appreciate the invaluable assistance of Dr. Andrea Kalinoski with confocal microscopy. All confocal images were acquired in the Marci Kaptor Advanced Imaging Center at the University of Toledo. We would like to thank Dr. Benoit Bruneau for the Cx40-pX2P reporter construct. We thank Simon Conway for helpful comments and suggestions.

This work was supported by the National Institutes of Health DK067064, NS040644 (to MJH); IP30-AG13319, 9730181N (to ABF).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi: 10.1016/j.ydbio.2010.02.001.

References

- Bancroft, M., Bellairs, R., 1976. The development of the notochord in the chick embryo, studied by scanning and transmission electron microscopy. J. Embryol. Exp. Morphol. 35, 383–401.
- Barbosa, A.C., Funato, N., Chapman, S., McKee, M.D., Richardson, J.A., Olson, E.N., Yanagisawa, H., 2007. Hand transcription factors cooperatively regulate development of the distal midline mesenchyme. Dev. Biol. 310, 154–168.
- Barnes, R.M., Firulli, A.B., 2009. A twist of insight—the role of Twist-family bHLH factors in development. Int. J. Dev. Biol. 53, 909–924.
- Barnett, J.V., Desgrosellier, J.S., 2003. Early events in valvulogenesis: a signaling perspective. Birth Defects Res. C. Embryo Today 69, 58–72.
- Bedard, J.E., Purnell, J.D., Ware, S.M., 2007. Nuclear import and export signals are essential for proper cellular trafficking and function of ZIC3. Hum. Mol. Genet. 16, 187–198.
- Bhattacharya, S., MacDonald, S.T., Farthing, C.R., 2006. Molecular mechanisms controlling the coupled development of myocardium and coronary vasculature. Clin. Sci. 111, 35–46.
- Brewer, S., Feng, W., Huang, J., Sullivan, S., Williams, T., 2004. Wnt1-Cre-mediated deletion of AP-2alpha causes multiple neural crest-related defects. Dev. Biol. 267, 135–152.
- Brooks, P.C., Clark, R.A., Cheresh, D.A., 1994. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569–571.
- Brou, C., Logeat, F., Gupta, N., Bessia, C., LeBail, O., Doedens, J.R., Cumano, A., Roux, P., Black, R.A., Israel, A., 2000. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell 5, 207–216.
- Bruneau, B.G., Nemer, G., Schmitt, J.P., Charron, F., Robitaille, L., Caron, S., Conner, D.A., Gessler, M., Nemer, M., Seidman, C.E., Seidman, J.G., 2001. A murine model of the Holt–Oram syndrome defines role of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 106, 709–721.
- Camenisch, T.D., Spicer, A.P., Brehm-Gibson, T., Biesterfeldt, J., Augustine, M.L., Calabro Jr., A., Kubalak, S., Klewer, S.E., McDonald, J.A., 2000. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Invest. 106, 349–360.
- Camenisch, T.D., Molin, D.G., Person, A., Runyan, R.B., Gittenberger-de Groot, A.C., McDonald, J.A., Klewer, S.E., 2002. Temporal and distinct TGFbeta ligand requirements during mouse and avian endocardial cushion morphogenesis. Dev. Biol. 248, 170–181.
- Conway, S.J., Henderson, D.J., Copp, A.J., 1997. Pax3 is required for cardiac neural crest migration in the mouse: evidence from the splotch (Sp2H) mutant. Development 124, 505–514.
- Conway, S.J., Bundy, J., Chen, J., Dickman, E., Rogers, R., Will, B.M., 2000. Decreased neural crest stem cell expansion is responsible for the conotruncal heart defects within the splotch (Sp(2H))/Pax3 mouse mutant. Cardiovasc. Res. 47, 314–328.
- Dahl, E., Winterhager, E., Traub, O., Willecke, K., 1995. Expression of gap junction genes, connexin40 and connexin43, during fetal mouse development. Anat. Embryol. (Berl). 191, 267–278.
- Danielian, P.S., Muccino, D., Rowitch, D.H., Michael, S.K., McMahon, A.P., 1998. Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase. Curr. Biol. 8, 1323–1326.
- Davis, E.M., Trinkaus, J.P., 1981. Significance of cell-to cell contacts for the directional movement of neural crest cells within a hydrated collagen lattice. J. Embryol. Exp. Morphol. 63, 29–51.
- de la Pompa, J.L., Timmerman, L.A., Takimoto, H., Yoshida, H., Elia, A.J., Samper, E., Potter, J., Wakeham, A., Marengere, L., Langille, B.L., Crabtree, G.R., Mak, T.W., 1998. Role of

the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature 392, 182–186.

- de Lange, F.J., Moorman, A.F., Anderson, R.H., Manner, J., Soufan, A.T., Gier-de Vries, C., Schneider, M.D., Webb, S., van den Hoff, M.J., Christoffels, V.M., 2004. Lineage and morphogenetic analysis of the cardiac valves. Circ. Res. 95, 645–654.
- Délot, E.C., 2003. Control of endocardial cushion and cardiac valve maturation by BMP signaling pathways. Mol. Genet. Metab. 80, 27–35.
- Dyer, L.A., Kirby, M.L., 2009. Sonic hedgehog maintains proliferation in secondary heart field progenitors and is required for normal arterial pole formation. Dev. Biol. 330, 305–317.
- Epstein, J.A., Li, J., Lang, D., Chen, F., Brown, C.B., Jin, F., Lu, M.M., Thomas, M., Liu, E., Wessels, A., Lo, C.W., 2000. Migration of cardiac neural crest cells in Splotch embryos. Development 127, 1869–1878.
- Ewart, J.L., Cohen, M.F., Meyer, R.A., Huang, G.Y., Wessels, A., Gourdie, R.G., Chin, A.J., Park, S.M., Lazatin, B.O., Villabon, S., Lo, C.W., 1997. Heart and neural tube defects in transgenic mice overexpressing the Cx43 gap junction gene. Development 124, 1281–1292.
- Ewen, M.E., 2009. Where the cell cycle and histones meet. Genes Dev. 14, 2265–2270.
- Firulli, A.B., 2003. A Handful of questions: the molecular biology of the heart and neural crest derivatives (Hand)-subclass of basic helix-loop-helix transcription factors. Gene 312, 27–40.
- Firulli, A.B., Thattaliyath, B.D., 2002. Transcription factors in cardiogenesis: the combinations that unlock the mysteries of the heart. Int. Rev. Cytol. 214, 1–62.
- Firulli, A.B., Maibenco, D.C., Kinniburgh, A.J., 1994. Triplex forming ability of a c-myc promoter element predicts promoter strength. Arch. Biochem. Biophys. 310 (1), 236–242.
- Firulli, B.A., Howard, M.J., McDaid, J.R., McIlreavey, L., Dionne, K.M., Centonze, V.E., Cserjesi, P., Virshup, D.M., Firulli, A.B., 2003. PKA, PKC, and the protein phosphatase 2A influence HAND factor function: a mechanism for tissue-specific transcriptional regulation. Mol. Cell 12, 1225–1237.
- Firulli, B.A., Krawchuk, D., Centonze, V.E., Vargesson, N., Virshup, D.M., Conway, S.J., Cserjesi, P., Laufer, E., Firulli, A.B., 2005. Altered Twist1 and Hand2 dimerization is associated with Saethre–Chotzen syndrome and limb abnormalities. Nat. Genet. 37, 373–381.
- Fischer, A., Schumacher, N., Maier, M., Sendtner, M., Gessler, M., 2004. The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev. 18, 901–911.
- Funato, N., Chapman, S.L., McKee, M.D., Funato, H., Morris, J.A., Shelton, J.M., Richardson, J.A., Yanagisawa, H., 2009. Hand2 controls osteoblast differentiation in the branchial arch by inhibiting DNA binding of Runx2. Develop 136, 615–625.
- Gammill, L.S., Gonzalez, C., Gu, C., Bronner-Fraser, M., 2006. Guidance of trunk neural crest migration requires neuropilin 2/semaphorin 3F signaling. Development 133, 99–106.
- Garry, D.J., Olson, E.N., 2006. A common progenitor at the heart of development. Cell 127, 1101–1104.
- Gitler, A.D., Lu, M.M., Jiang, Y.Q., Epstein, J.A., Gruber, P.J., 2003. Molecular markers of cardiac endocardial cushion development. Dev. Dyn. 228, 643–650.
- Goodwin, R.L., Nesbitt, T., Price, R.L., Wells, J.C., Yost, M.J., Potts, J.D., 2005. Threedimensional model system of valvulogenesis. Dev. Dyn. 233, 122–129.
- Hendershot, T.J., Liu, H., Sarkar, A.A., Giovannucci, D.R., Clouthier, D.E., Abe, M., Howard, M.J., 2007. Expression of Hand2 is sufficient for neurogenesis and cell type-specific gene expression in the enteric nervous system. Dev. Dyn. 236, 93–105.
- Hendershot, T.J., Liu, H., Clouthier, D.E., Shepherd, I.T., Coppola, E., Studer, M., Firulli, A. B., Pittman, D.L., Howard, M.J., 2008. Conditional deletion of Hand2 reveals critical functions in neurogenesis and cell type-specific gene expression for development of neural crest-derived noradrenergic sympathetic ganglion neurons. Dev. Biol. 319, 179–191.
- Horiuchi, K., Zhou, H.M., Kelly, K., Manova, K., Blobel, C.P., 2005. Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev. Biol. 283, 459–471.
- Howard, M.J., 2005. Mechanisms and perspectives on differentiation of autonomic neurons. Dev. Biol. 277, 271–286.
- Howard, M.J., Foster, D.N., Cserjesi, P., 1999. Expression of HAND gene products may be sufficient for the differentiation of avian neural crest-derived cells into catecholaminergic neurons in culture. Dev. Biol. 215, 62–77.
- Howard, M.J., Stanke, M., Schneider, C., Wu, X., Rohrer, H., 2000. The transcription factor dHAND is a downstream effector of BMPs in sympathetic neuron specification. Development 127 (18), 4073–4081.
- Huang, G.Y., Cooper, E.S., Waldo, K., Kirby, M.L., Gilula, N.B., Lo, C.W., 1998. Gap junction-mediated cell-cell communication modulates mouse neural crest migration. J. Cell Biol. 143, 1725–1734.
- Huang, J., Bridges, L.C., White, J.M., 2005. Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol. Biol. Cell 16, 4982–4991.
- Hutson, M.R., Kirby, M.L., 2007. Model systems for the study of heart development and disease. Cardiac neural crest and conotruncal malformations. Semin. Cell Dev. Biol. 18, 101–110.
- Jaeger, S., Barends, S., Giege, R., Eriani, G., Martin, F., 2005. Expression of metazoan replication-dependent histone genes. Biochimie 87, 827–834.
- Jia, Q., McDIll, B.W., Li, S.-Z., Deng, C., Chang, C.-P., Chen, F., 2007. Smad signaling in the neural crest regulates cardiac outflow tract remodeling through cell autonomous and non-cell autonomous effects. Dev. Biol. 311, 172–184.
- Jiang, X., Rowitch, D.H., Soriano, P., McMahon, A.P., Sucov, H.M., 2000. Fate of the mammalian cardiac neural crest. Development 127, 1607–1616.
- Jiang, X., Choudhary, B., Merki, E., Chien, K.R., Maxson, R.E., Sucov, H.M., 2002. Normal fate and altered function of the cardiac neural crest cell lineage in retinoic acid receptor mutant embryos. Mech. Dev. 117, 115–122.

- Kaufman, C.K., Zhou, P., Pasolli, H.A., Rendl, M., Bolotin, D., Lim, K.C., Dai, X., Alegre, M.L., Fuchs, E., 2003. GATA-3: an unexpected regulator of cell lineage determination in skin. Genes Dev. 17, 2108–2122.
- Kelly, R.G., Buckingham, M.E., 2002. The anterior heart-forming field: voyage to the arterial pole of the heart. Trends Genet. 18, 210–216.
- Kirchhoff, S., Kim, J.S., Hagendorff, A., Thonnissen, E., Kruger, O., Lamers, W.H., Willecke, K., 2000. Abnormal cardiac conduction and morphogenesis in connexin40 and connexin43 double deficient mice. Circ. Res. 87, 399–405.
- Kisanuki, Y.Y., Hammer, R.E., Miyazaki, J., Williams, S.C., Richardson, J.A., Yanagisawa, M., 2001. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 230, 230–242.
- Komatsu, K., Wakatsuki, S., Yamada, S., Yamamura, K., Miyazaki, J., Sehara-Fujisawa, A., 2007. Meltrin beta expressed in cardiac neural crest cells is required for ventricular septum formation of the heart. Dev. Biol. 303. 82–92.
- Kume, T., Jiang, H., Topczewska, J.M., Hogan, B.L., 2001. The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis. Genes Dev. 15, 2470–2482.
- Kuriyama, S., Mayor, R., 2008. Molecular analysis of neural crest migration. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363 (1495), 1349–1362.
- Lamers, W.H., Mooreman, A.F., 2002. Cardiac septation: a late contribution of the embryonic primary myocardium to heart morphogenesis. Circ. Res. 91, 93–103.
- Lan, M.S., Breslin, M.B., 2009. Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation. FASEB J. 23, 2024–2033.
- Lie-Venema, H., van den Akker, N.M., Bax, N.A., Winter, E.M., Maas, S., Kekarainen, T., Hoeben, R.C., deRuiter, M.C., Poelmann, R.E., Gittenberger-de Groot, A.C., 2007. Origin, fate, and function of epicardium-derived cells (EPDCs) in normal and abnormal cardiac development. ScientificWorldJournal 12, 1777–1798.
- Lim, K.C., Lakshmanan, G., Crawford, S.E., Gu, Y., Grosveld, F., Engel, J.D., 2000. Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat. Genet. 25, 209–212.
- Liu, A., Wang, B., Niswander, L.A., 2005a. Mouse intraflagellar transport proteins regulate both the activator and repressor functions of Gli transcription factors. Development 132, 3103–3111.
- Liu, H., Margiotta, J.F., Howard, M.J., 2005b. BMP4 supports noradrenergic differentiation by a PKA-dependent mechanism. Dev. Biol. 286, 521–536.
- Liu, W.-D., Wang, H.-W., Muguira, M., Breslin, M.B., Law, M.S., 2006. INSM1 functions as a transcriptional repressor of the neuroD/b2 gene through the recruitment of cyclin D1 and histone deacetylases. Biochem. J. 397, 169–177.
- Lo, L., Sommer, L., Anderson, D.J., 1997. MASH1 maintains competence for BMP2induced neuronal differentiation in post-migratory neural crest cells. Curr. Biol. 7, 440–450.
- Lowenstein, W.R., 1988. Genetic regulation of cell-to-cell communication. Braz. J. Med. Biol. Res. 21, 1213–1223.
- Malumbres, M., Barbacid, M., 2005. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 30, 630–641.
- Marzluff, W.F., Gongidi, P., Woods, K.R., Jin, J., Maltais, L.J., 2002. The human and mouse replication-dependent histone genes. Genomics 80, 487–498.
- McFadden, D.G., Charite, J., Richardson, J.A., Srivastava, D., Firulli, A.B., Olson, E.N., 2000. A GATA-dependent right ventricular enhancer controls dHAND transcription in the developing heart. Development 127, 5331–5341.
- McFadden, D.G., Barbosa, A.C., Richardson, J.A., Schneider, M.D., Srivastava, D., Olson, E.N., 2005. The Hand1 and Hand2 transcription factors regulate expansion of the embryonic cardiac ventricles in a gene dosage-dependent manner. Development 132, 189–201.
- Mégarbané, A., Salem, N., Stephan, E., Ashooush, R., Lenoir, D., Delague, V., Kassab, R., Loiselet, J., Bouvagnet, P., 2000. X-linked transposition of the great arteries and incomplete penetrance among males with a nonsense mutation in ZIC3. Eur. J. Hum. Gen. 8, 704–708.
- Mitchell, M.E., Sander, T.L., Klinker, D.B., Tomita-Mitchell, A., 2007. The molecular basis of congenital heart disease. Semin. Thorac. Cardiovasc. Surg. 19, 228–237.
- Morikawa, Y., Cserjesi, P., 2008. Cardiac neural crest expression of Hand2 regulates outflow and second heart field development. Circ. Res. 103, 1422–1429.
- Morikawa, Y., D'Autreaux, F., Gershon, M.D., Cserjesi, P., 2007. Hand2 determines the noradrenergic phenotype in the mouse sympathetic nervous system. Dev. Biol. 307, 114–126.
- Morrison-Graham, K., Schatteman, G.C., Bork, T., Bowen-Pope, D.F., Weston, J.A., 1992. A PDGF receptor mutation in the mouse (Patch) perturbs the development of a nonneuronal subset of neural crest-derived cells. Development 115, 133–142.
- Niessen, K., Karsan, A., 2008. Notch signaling in cardiac development. Circ. Res. 102, 1169–1181.
- Obler, D., Juraszek, A.L., Smoot, L.B., Natowicz, M.R., 2008. Double outlet right ventricle: aetiologies and associations. J. Med. Genet. 45, 481–497.
- Olson, E.N., 2006. Gene regulatory networks in the evolution and development of the heart. Science 313, 1922–1927.
- Orr-Urtreger, A., Lonai, P., 1992. Platelet-derived growth factor-A and its receptor are expressed in separate, but adjacent cell layers of the mouse embryo. Development 115, 1045–1058.
- Parlier, D., Ariza, A., Christulia, F., Geneco, F., Vanhomwegen, J., Kricha, S., Souopgui, J., Bellefroid, E.J., 2008. *Xenopus* zinc finger transcription factor IA1 (Insm1) expression marks anteroventral noradrenergic neuron progenitors in *Xenopus* embryos. Dev. Dyn. 237, 2147–2157.
- Person, A.D., Klewer, S.E., Runyan, R.B., 2005. Cell biology of cardiac cushion development. Int. Rev. Cytol. 243, 287–335.
- Pinco, K.A., Liu, S., Yang, J.T., 2001. Alpha4 integrin is expressed in a subset of cranial neural crest cells and in epicardial progenitor cells during early mouse development. Mech. Dev. 100, 99–103.

Poelmann, R.E., Mikawa, T., Gittenberger-de Groot, A.C., 1998. Neural crest cells in outflow tract septation of the embryonic chicken heart: differentiation and apoptosis. Dev. Dyn. 212, 373–384.

Qui, G.R., Gong, L.G., He, G., Xu, X.Y., Xin, N., Sun, G.F., Yuan, Y.H., Sun, K.L., 2006. Association of the GLI gene with ventricular septal defect after the susceptibility gene being narrowed to 3.56 cM in 12q13. Chin. Med. J. (Engl.) 119, 267–274.

Raible, D.W., Eisen, J.S., 1996. Regulative interactions in zebrafish neural crest. Development 122, 501–507.

Raid, R., Krinka, D., Bakhoff, L., Abdelwahid, E., Jokin, E., Kärner, M., Malva, M., Meier, R., Pelliniemi, L.J., Ploom, M., Sizarov, A., Pooga, M., Karis, A., 2009. Lack of Gata3 results in conotruncal heart anomalies in mouse. Mech. Dev. 126, 80–89.

Ranger, A.M., Grusby, M.J., Hodge, M.R., Gravallese, E.M., Charles de la Brousse, F., Hoey, T., Mickanin, C., Baldwin, H.S., Glimcher, L.H., 1998. The transcription factor NF-ATc is essential for cardiac valve formation. Nature 392, 186–190.

Reaume, A.G., de Sousa, P.A., Kulkarni, S., Langille, B.L., Zhu, D., Davies, T.C., Juneja, S.C., Kidder, G.M., Rossant, J., 1995. Cardiac malformation in neonatal mice lacking connexin43. Science 267, 1831–1834.

Runyan, R.B., Markwald, R.R., 1983. Invasion of mesenchyme into three-dimensional collagen gels: a regional and temporal analysis of interaction in embryonic heart tissue. Dev. Biol. 95, 108–114.

Sakata, Y., Kamei, C.N., Nakagami, H., Bronson, R., Liao, J.K., Chin, M.T., 2002. Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/ Hey2. Proc. Natl. Acad. Sci. 99, 16197–16202.

Sanderson, J., 1994. Biological Microtechnique (Royal Microscopical Society Microscopy Handbooks). Garland Science, London, pp. 163–170.

Schmidt, M., Lin, S., Pape, M., Ernsberger, U., Howard, M.J., Rohrer, H., 2009. The bHLH transcription factor Hand2 is essential for the maintenance of noradrenergic properties in differentiated sympathetic neurons. Dev. Biol. 329, 191–200.

Seo, S., Fujita, H., Nakano, A., Kang, M., Duarte, A., Kume, T., 2006. The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development. Dev. Biol. 294, 458–470.

Seul, K.H., Tadros, P.N., Beyer, E.C., 1997. Mouse connexin40: gene structure and promoter analysis. Genomics 46, 120–126.

Sheppard, A.M., Onken, M.D., Rosen, G.D., Noakes, P.G., Dean, D.C., 1994. Expanding roles for alpha 4 integrin and its ligands in development. Cell Adhes. Commun. 2, 27–43.

Simon, A.M., McWhorter, A.R., Dones, J.A., Jackson, C.L., Chen, H.D.R., 2004. Heart and head defects in mice lacking pairs of connexins. Dev. Biol. 265, 369–383.

Singh, M.K., Nicolas, E., Gherraby, W., Dadke, D., Lessin, S., Golemis, E.A., 2007. HEI10 negatively regulates cell invasion by inhibiting cyclin B/Cdk1 and other promotility proteins. Oncogene 26, 4825–4832.

Snarr, B.S., Kern, C., Wessels, A., 2008. Origins and fate of cardiac mesenchyme. Dev. Dyn. 237, 2804–2819.

Snider, P., Olaopa, M., Firulli, A.B., Conway, S.J., 2007. Cardiovascular development and the colonizing cardiac neural crest lineage. Sci. World J. 7, 1090–1113.

Sock, E., Rettig, S.D., Enderich, J., Bosl, M.R., Tamm, E.R., Wegner, M., 2004. Gene targeting reveals a widespread role for the high-mobility-group transcription factor Sox11 in tissue remodeling. Mol. Cell. Biol. 24, 6635–6644.

Song, W., Jackson, K., McGuire, P.G., 2000. Degradation of type IV collagen by matrix metalloproteinases is an important step in the epithelial–mesenchymal transformation of the endocardial cushions. Dev. Biol. 222, 606–617.

Srivastava, D., 1999. HAND proteins: molecular mediators of cardiac development and congenital heart disease. Trends Cardiovasc. Med. 9, 11–18.

Srivastava, D., 2006. Making or breaking the heart: form lineage determination to morphogenesis. Cell 126, 1037–1048.

Srivastava, D., Olson, E.N., 2000. A genetic blueprint for cardiac development. Nature 407, 221–226.

Srivastava, D., Cserjesi, P., Olson, E.N., 1995. A subclass of bHLH proteins required for cardiac morphogenesis. Science 270, 1995–1999.

Srivastava, D., Thomas, T., Lin, Q., Kirby, M.L., Brown, D., Olson, E.N., 1997. Regulation of cardiac mesodermal and neural crest development by the bHLH transcription factor, dHAND. Nat. Genet. 16, 154–160.

Stamataki, D., Ulloa, F., Tsoni, S.V., Mynett, A., Briscoe, J., 2005. A gradient of Gli activity mediates graded Sonic Hedgehog signaling in the neural tube. Genes Dev. 19, 626–641.

Stoller, J.Z., Epstein, J.A., 2005. Cardiac neural crest. Sem. Cell Dev. Biol. 16, 704–715.

Sullivan, R., Huang, G.Y., Meyer, R.A., Wessels, A., Linask, K.K., Lo, C.W., 1998. Heart malformations in transgenic mice exhibiting dominant negative inhibition of gap junctional communication in neural crest cells. Dev. Biol. 204, 224–234.

te Welscher, P., Zuniga, A., Kuijper, S., Drenth, T., Goedemans, H.J., Meijlink, F., Zeller, R., 2002a. Progression of vertebrate limb development through SHH-mediated counteraction of gli3. Science 298, 827–830.

te Welscher, P., Fernandez-Terran, M., Ros, M.A., Zeller, R., 2002b. Mutual genetic antagonism involving GLI3 and dHAND prepatterns the vertebrate limb bud mesenchyme prior to SHH signaling. Genes Dev. 16, 421–426.

Thomas, S.A., Matsumoto, A.M., Palmiter, R.D., 1995. Noradrenaline is essential for mouse fetal development. Nature 374, 643–646.

Thomas, T., Yamagishi, H., Overbeek, P.A., Olson, E.N., Srivastava, D., 1998. The bHLH factors, dHAND and eHAND, specify pulmonary and systemic cardiac ventricles independent of left-right sidedness. Dev. Biol. 196, 228–236.

Toby, G.G., Gherraby, W., Coleman, T.R., Golemis, E.A., 2003. A novel RING finger protein, human enhancer of invasion 10, alters mitotic progression through regulation of cyclin B levels. Mol. Cell. Biol. 23, 2109–2122.

Todorovic, V., Frendewey, D., Gutstein, D.E., Cehn, Y., Freyer, L., Finnegan, E., Liu, F., Murphy, A., Valenzuela, D., Yancopoilos, G., Rifkin, D.B., 2007. Long form of latent TGF-b binding protein 1(Ltbp1L) is essential for cardiac outflow tract septation and remodeling. Development 134, 3723–3732.

Togi, K., Yoshida, Y., Matsumae, H., Nakashima, Y., Kita, T., Tanaka, M., 2006. Essential role of Hand2 in interventricular septum formation and trabeculation during cardiac development. Biochem. Biophys. Res. Commun. 343, 144–151.

Waldo, K., Miyagawa-Tomita, S., Kumiski, D., Kirby, M.L., 1998. Cardiac neural crest cells provide new insight into septation of the cardiac outflow tract: aortic sac to ventricular septal closure. Dev. Biol. 196, 129–144.

Waldo, K.L., Lo, C.W., Kirby, M.L., 1999. Connexin 43 expression reflects neural crest patterns during cardiovascular development. Dev. Biol. 208, 307–323.

Wang, B., Weidenfeld, J., Lu, M.M., Maika, S., Kuziel, W.A., Morrisey, E.E., Tucker, P.W., 2004. Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 131, 4477–4487.

Ware, S.M., Harutyunyan, K.G., Belmont, J.W., 2006. Heart defects in X-linked heterotaxy: evidence for a genetic interaction of Zic3 with the nodal signaling pathway. Dev. Dyn. 235, 1631–1637.

Webb, S., Brown, N.A., Anderson, R.H., 1998. Formation of the atrioventricular septal structures in the normal mouse. Circ. Res. 82, 645–656.

Wildner, H., Gierl, M.S., Strehle, M., Pla, P., Birchmeier, C., 2008. Insm1 (IA-1) is a crucial component of the transcriptional network that controls differentiation of the sympatho-adrenal lineage. Development 135, 473–481.

Wu, X., Howard, M.J., 2002. Transcripts encoding HAND genes are differentially expressed and regulated by BMP4 and GDNF in developing avian gut. Gene Expr. 10, 279–293.

Xie, J., Cai, T., Zhang, H., Lan, M.S., Notkins, A.L., 2002. The zinc-finger transcription factor INSM1 is expressed during embryo development and interacts with the Cblassociated protein. Genomics 80, 54–61.

Xu, H., Firulli, A.B., Zhang, X., Howard, M.J., 2003. HAND2 synergistically enhances transcription of dopamine-b-hydroxylase in the presence of Phox2a. Dev. Biol. 262, 183–193.

Xu, H., Morishima, M., Wylie, J.N., Schwartz, R.J., Burneau, B.G., Lindsay, E.A., Baldini, A., 2004. Tbx1 has a dual role in the morphogenesis of the cardiac outflow tract. Development 131, 3217–3227.

Yamagishi, H., Yamagishi, C., Nakagawa, O., Harvey, R.P., Olson, E.N., Srivastava, D., 2001. The combinatorial activities of Nkx2.5 and dHAND are essential for cardiac ventricle formation. Dev. Biol. 239, 190–203.

Yanagisawa, H., Clouthier, D.E., Richardson, J.A., Charite', J., Olson, E.N., 2003. Targeted deletion of a branchial arch-specific enhancer reveals a role of dHAND in craniofacial development. Development 130, 1069–1078.

Yang, J.T., Rayburn, H., Hynes, R.O., 1995. Cell adhesion events mediated by a4 integrins are essential in placental and cardiac development. Development 121, 549–560.

Yelbuz, T.M., Waldo, K.L., Kumiski, D.H., Stadt, H.A., Wolfe, R.R., Leatherbury, L., Kirby, M. L., 2002. Circulation 106, 504–510.

Young, H.M., Ciampoli, D., Hsuan, J., Canty, A.J., 1999. Expression of Ret-, p75(NTR)-, Phox2a-, Phox2b-, and tyrosine hydroxylase-immunoreactivity by undifferentiated neural crest-derived cells and different classes of enteric neurons in the embryonic mouse gut. Dev. Dyn. 216, 137–152.

Young, B.A., Taooka, Y., Liu, S., Askins, K.J., Yokosaki, Y., Thomas, S.M., Sheppard, D., 2001. The cytoplasmic domain of the integrin alpha9 subunit requires the adaptor protein paxillin to inhibit cell spreading but promotes cell migration in a paxillinindependent manner. Mol. Biol. Cell 12, 3214–3225.

Zang, M.X., Li, Y., Wang, H., Wang, J.B., Jia, H.T., 2004. Cooperative interactions between the basic helix–loop–helix transcription factor dHand and myocyte enhancer factor 2C regulates myocardial gene expression. J. Biol. Chem. 279 (52), 54258–54263.

Zhang, H., Zhou, L., Yang, R., Sheng, Y., Sum, W., Kong, X., Cao, K., 2006. Identification of differentially expressed genes in human heart with ventricular septal defect using suppression subtractive hybridization. BBRC 342, 135–144.

Zhang, T., Liu, W.D., Saunee, N.A., Breslin, M.B., Lan, M.S., 2009. Zinc finger transcription factor INSM1 interrupts cyclin D1 and CDK4 binding and induces cell cycle arrest. J. Biol. Chem. 284, 5574–5581.

Zhao, J., Kennedy, B.K., Lawrence, B.D., Barbie, D.A., Matera, A.G., Fletcher, J.A., Harlow, E., 2000. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev. 14, 2283–2297.

Zhou, Q.Y., Palmiter, R.D., 1995. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83, 1197–1209.

Zhou, B., Cron, R.Q., Wu, B., Genin, A., Wang, Z., Liu, S., Robson, P., Baldwin, H.S., 2002. Regulation of the murine Nfatc1 gene by NFATc2. J. Biol. Chem. 277, 10704–10711.

Zhou, X., Nai, Q., Chen, M., Dittus, J.D., Howard, M.J., Margiotta, J.F., 2004. Brain-derived neurotrophic factor and trkB signaling in parasympathetic neurons: relevance to regulating alpha7-containing nicotinic receptors and synaptic function. J. Neurosci. 24, 4340–4350.